



James Ford

Professor of Medicine (Oncology) and of Genetics and, by courtesy, of Pediatrics
Medicine - Oncology

 NIH Biosketch available Online

CLINICAL OFFICE (PRIMARY)

- **Clinical Cancer and Genomics**

900 Blake Wilbur Dr

3rd Fl MC 5844

Stanford, CA 94305

Tel (650) 498-6000

Fax (650) 725-2441

ACADEMIC CONTACT INFORMATION

- **Alternate Contact**

Donna Galvez

Email drgalvez@stanford.edu

Tel 721-1503

Bio

BIO

Dr. Ford is a medical oncologist and geneticist at Stanford, devoted to studying the genetic basis of breast and GI cancer development, treatment and prevention. Dr. Ford graduated in 1984 Magna Cum Laude (Biology) from Yale University where he later received his M.D. degree from the School of Medicine in 1989. He was an internal medicine resident (1989-91), Clinical Fellow in Medical Oncology (1991-94), Research Fellow of Biological Sciences (1993-97) at Stanford, and joined the faculty in 1998. He is currently Professor of Medicine (Oncology) and Genetics, and Director of the Stanford Cancer Genetics Clinic and the Cancer Genomics Program at the Stanford University Medical Center.

Dr. Ford's research goals are to understand the role of genetic changes in cancer genes in the risk and development of common cancers. He studies the role of the p53 and BRCA1 tumor suppressor genes in DNA repair, and uses techniques for high-throughput genomic analyses of cancer to identify molecular signatures for targeted therapies. Dr. Ford's clinical interests include the diagnosis and treatment of patients with a hereditary pre-disposition to cancer. He runs the Stanford Cancer Genetics Clinic, that sees patients for genetic counseling and testing of hereditary cancer syndromes for prevention and early diagnosis of cancer in high-risk individuals and populations. He has recently been named the Director of Stanford's new Cancer Genomics Program, performing next-generation tumor profiling to identify novel genetic targets for personalized targeted therapies, and directs the Molecular Tumor Board.

Dr. Ford is an editor of numerous scientific journals, including Cancer Research, DNA Repair, and PLoS Genetics. He has recently been named the founding Editor-in-Chief of JCO Precision Oncology.

CLINICAL FOCUS

- Cancer > GI Oncology
- Cancer Genetics
- Gastrointestinal Cancers - Genetics

- Gastrointestinal Cancers - Medical Oncology
- Breast Cancer - Genetics
- Ovarian Cancer - Genetics
- Medical Oncology
- Molecular Tumor Board

ACADEMIC APPOINTMENTS

- Professor, Medicine - Oncology
- Professor, Genetics
- Professor (By courtesy), Pediatrics
- Member, Bio-X
- Member, Stanford Cancer Institute

ADMINISTRATIVE APPOINTMENTS

- Founding Director, Stanford Clinical Cancer Genetics Program, (2000- present)
- Director, Oncology Fellowship Training Program, (2002-2015)
- Director, Stanford Clinical Cancer Genomics, (2013- present)
- Associate Director of Education and Training, Stanford Cancer Institute, (2018- present)

HONORS AND AWARDS

- Member, Western Society for Clinical Investigation (2007)
- Top Doctor for Cancer, Castle Connolly (2008 -)
- Council Chair, California Breast Cancer Research Program (2009 - 10)
- Medical Oncology, Best Doctors in America (2013 -)
- Editor-in-Chief, JCO Precision Oncology Journal (2016 - 2020)
- FASCO, ASCO (2017)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Board of Directors, Gastric Cancer Foundation (2008 - 2017)
- Scientific Advisory Board, V Foundation (2006 - present)
- Member, ASCO Cancer Prevention Committee (2013 - 2016)

PROFESSIONAL EDUCATION

- Medical Education: Yale School Of Medicine (1989) CT
- Fellowship: Stanford University Hematology and Oncology Fellowship (1994) CA
- Residency: Stanford University Internal Medicine Residency (1991) CA
- Internship: Stanford University Internal Medicine Residency (1990) CA
- M.D., Yale Medical School , Medicine (1989)
- Board Certification: Medical Oncology, American Board of Internal Medicine (2005)
- Maintenance of Certification, Medical Oncology , American Board of Internal Medicine (2015)

COMMUNITY AND INTERNATIONAL WORK

- The Hong Kong High Risk Breast Cancer Programme and Family Registry

LINKS

- Video Story: <https://stanfordhealthcare.org/stanford-health-care-now/why-i-got-into-medicine/why-medicine-james-ford-md.html>
- Ford Lab Site: <http://jamesfordlab.stanford.edu/>
- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

The major investigative focus of this laboratory and translational research program is to explore the mammalian genetic determinants of the inducible response and cellular sensitivity to DNA damage, focusing particularly on the effects of the p53 and BRCA1 gene products on DNA repair and cancer susceptibility. We have found that loss of p53 and BRCA1 function results in defective repair of DNA damage, including effects on homologous recombination, nucleotide and base-excision repair. In addition, we are exploring ways to exploit the DNA repair deficiency of p53 and BRCA1 mutant cancer cells and to identify targeted therapeutic approaches for the treatment and prevention of related cancers.

Role of BRCA1 in base-excision DNA repair (BER): BRCA1 appears to have complex regulatory effects on multiple DNA repair pathways in addition to their shared role in homologous-recombination and DNA double strand break repair. We first described that breast cancer cell lines mutant for the BRCA1 gene exhibit sensitivity to oxidative DNA damage. We also developed a novel viral based “host-cell reactivation” assay to measure the repair of oxidative DNA damage in living cells using an adenoviral GFP reporter gene, and demonstrated that BRCA1 mutant cells were defective in BER.

Discovery of small molecules that activate BER and may prevent BRCA1-associated tumors: We designed and performed a high-throughput screen to identify small-molecules that enhance DNA repair in a BRCA1 mutant background, and thus may serve as candidate agents for prevention of cancer by enhancing DNA repair and interrupting multistep mutagenesis. Several of these drugs are potentially “repurposeable” and are currently or were previously used in humans for other indications. We have shown activity of two in preventing the development of BRCA1-associated breast cancers in mice and are developing plans for a clinical trial using the lead hit for prevention of BRCA1-associated premalignant changes in ovaries from women undergoing risk-reducing bilateral oophorectomies.

Clinical translation of Next-Generation Sequencing for hereditary cancer risk assessment: We recently led the first clinical study of next-generation gene panel DNA sequencing among women referred for breast cancer risk assessment using germline DNA samples from our large translational research biobank containing more than 2000 specimens, all donated by individuals tested for BRCA1/2 or other gene mutations. We found that >10% of patients had potentially pathogenic mutations in genes other than BRCA1/2, thus doubling the rate of identified germline cancer susceptibility gene alterations in this population, a discovery that has enabled early detection of cancers.

Targeting TNBC and other malignancies with DNA damaging drugs and PARP: We found through preclinical studies and clinical trials that nearly all BRCA mutation associated breast cancer, and approximately half of non-BRCA mutant TNBC exhibit clinical sensitivity to platinum chemotherapy and synthetic lethality with PARP inhibitors. As part of these efforts, we performed extensive correlative studies on tumor tissue and germline DNA samples obtained from patients enrolled in a large, multi-institutional neoadjuvant clinical trial, using gene expression microarrays, DNA copy-number analyses, and germline DNA sequencing. We described a bioinformatic measure of homologous recombination deficiency (HRD) that is highly predictive of clinical response in these patients. Our current and future research goals in this area is to leverage our expertise in germline and tumor genomics to identify patients with breast and other cancers harboring DNA repair gene defects and HRD for treatment using PARP inhibitors and other DNA repair directed therapies (ATR and DNA-PK inhibitors). We have also developed breast cancer cell lines resistant to PARP-inhibitors and are exploring the mechanism for this drug resistance.

CLINICAL TRIALS

- A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy), Recruiting
- Assessments of Genetic Counseling Augmented With an Educational Video or Pamphlet Versus Traditional Counseling, Recruiting
- Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma, Recruiting
- Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples, Recruiting
- Genomic Profiling in Recommending Treatment for Patients With Metastatic Solid Tumors, Recruiting
- Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With AKT Mutations, A ComboMATCH Treatment Trial, Recruiting
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial, Recruiting
- The Gastric Cancer Foundation: A Gastric Cancer Registry, Recruiting
- Comprehensive Screening for Women at High Genetic Risk for Developing Breast Cancer, Not Recruiting
- My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors, Not Recruiting
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial), Not Recruiting

Teaching

STANFORD ADVISEES

Postdoctoral Faculty Sponsor

Samyuktha Suresh

Postdoctoral Research Mentor

Samyuktha Suresh

GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Cancer Biology (Phd Program)
- Genetics (Phd Program)
- Medicine (Masters Program)

Publications

PUBLICATIONS

- **Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes.** *Breast cancer research and treatment*
Lenz, L., Neff, C., Solimeno, C., Cogan, E. S., Abramson, V. G., Boughey, J. C., Falkson, C., Goetz, M. P., Ford, J. M., Gradishar, W. J., Jankowitz, R. C., Kaklamani, V. G., Marcom, et al
2023
- **The New NCI Precision Medicine Trials.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Harris, L. N., Blanke, C. D., Erba, H. P., Ford, J. M., Gray, R. J., LeBlanc, M. L., Hu-Lieskovan, S., Litzow, M. R., Luger, S. M., Meric-Bernstam, F., O'Dwyer, P. J., Othus, M. K., Politi, et al
2023
- **Clinical implications of conflicting variant interpretations in the cancer genetics clinic.** *Genetics in medicine : official journal of the American College of Medical Genetics*
Zukin, E., Culver, J. O., Liu, Y., Yang, Y., Ricker, C. N., Hodan, R., Sturgeon, D., Kingham, K., Chun, N. M., Rowe-Teeter, C., Singh, K., Zell, J. A., Ladabaum, et al
2023: 100837

- **Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers.** *Nature communications*
Harding, J. J., Piha-Paul, S. A., Shah, R. H., Murphy, J. J., Cleary, J. M., Shapiro, G. I., Quinn, D. I., Brana, I., Moreno, V., Borad, M., Loi, S., Spanggaard, I., Park, et al
2023; 14 (1): 630
- **Therapeutic Implications of Oncogenic Missense HER2 (ERBB2) Mutations in Gastric Adenocarcinoma.** *JCO precision oncology*
King, D. A., Weiel, J. J., Reyes, R., Mills, M., Itchon, A., Fisher, G. A., Ford, J. M., Suarez, C. J.
2023; 7: e2200093
- **National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH).** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Meric-Bernstam, F., Ford, J. M., O'Dwyer, P. J., Shapiro, G. I., McShane, L. M., Freidlin, B., O'Ceirbhail, R. E., George, S., Glade Bender, J., Lyman, G. H., Tricoli, J. V., Patton, D., Hamilton, et al
2023
- **A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes.** *Nature cancer*
Gruber, J. J., Afghahi, A., Timms, K., DeWees, A., Gross, W., Aushev, V. N., Wu, H., Balcioglu, M., Sethi, H., Scott, D., Foran, J., McMillan, A., Ford, et al
2022
- **Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.** *Annals of oncology : official journal of the European Society for Medical Oncology*
Geyer, C. E., Garber, J. E., Gelber, R. D., Yothers, G., Taboada, M., Ross, L., Rastogi, P., Cui, K., Arahmani, A., Aktan, G., Armstrong, A. C., Arnedos, M., Balmaña, et al
2022
- **Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer.** *Gynecologic oncology*
Hou, J. Y., Chapman, J. S., Kalashnikova, E., Pierson, W., Smith-McCune, K., Pineda, G., Vattakalam, R. M., Ross, A., Mills, M., Suarez, C. J., Davis, T., Edwards, R., Boisen, et al
2022
- **Somatic tumor mutations in moderate risk cancer genes: Targets for germline confirmatory testing.** *Cancer genetics*
Llorin, H., Graf, M., Chun, N., Ford, J.
2022; 268-269: 22-27
- **Enhancing Repair of Oxidative DNA Damage with Small-Molecule Activators of MTH1.** *ACS chemical biology*
Lee, Y., Onishi, Y., McPherson, L., Kietrys, A. M., Hebenbrock, M., Jun, Y. W., Das, I., Adimoolam, S., Ji, D., Mohsen, M. G., Ford, J. M., Kool, E. T.
2022
- **The Gastric Cancer Registry: A Genomic Translational Resource for Multidisciplinary Research in Gastric Cancer.** *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*
Almeda, A. F., Grimes, S. M., Lee, H., Greer, S., Shin, G., McNamara, M., Hooker, A. C., Arce, M. M., Kubit, M., Schauer, M. C., Van Hummelen, P., Ma, C., Mills, et al
2022
- **Single-cell analyses define a continuum of cell state and composition changes in the malignant transformation of polyps to colorectal cancer.** *Nature genetics*
Becker, W. R., Nevins, S. A., Chen, D. C., Chiu, R., Horning, A. M., Guha, T. K., Laquindanum, R., Mills, M., Chaib, H., Ladabaum, U., Longacre, T., Shen, J., Esplin, et al
2022
- **Personalised Risk Prediction in Hereditary Breast and Ovarian Cancer: A Protocol for a Multi-Centre Randomised Controlled Trial.** *Cancers*
Archer, S., Fennell, N., Colvin, E., Laquindanum, R., Mills, M., Dennis, R., Stutzin Donoso, F., Gold, R., Fan, A., Downes, K., Ford, J., Antoniou, A. C., Kurian, et al
2022; 14 (11)
- **A Novel Framework for the Next Generation of Precision Oncology Targets.** *JAMA oncology*
Chen, C. T., Ford, J. M.
2022
- **Somatic tumor testing implications for Lynch syndrome germline genetic testing.** *Cancer genetics*

- Barrus, K., Purington, N., Chun, N., Ladabaum, U., Ford, J. M.
2022; 264-265: 16-22
- **A phase II clinical trial of talazoparib monotherapy for PALB2 mutation-associated advanced breast cancer.**
Gruber, J., Gross, W., McMillan, A., Ford, J. M., Telli, M. L.
LIPPINCOTT WILLIAMS & WILKINS.2021
 - **Hereditary diffuse gastric cancer: updated clinical practice guidelines** *LANCET ONCOLOGY*
Blair, V. R., McLeod, M., Carneiro, F., Coit, D. G., D'Addario, J. L., Dieren, J., Harris, K. L., Hoogerbrugge, N., Oliveira, C., van der Post, R. S., Arnold, J., Benusiglio, P. R., Bisseling, et al
2020; 21 (8): E386–E397
 - **The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution.** *Cell*
Rozenblatt-Rosen, O., Regev, A., Oberdoerffer, P., Nawy, T., Hupalowska, A., Rood, J. E., Ashenberg, O., Cerami, E., Coffey, R. J., Demir, E., Ding, L., Esplin, E. D., Ford, et al
2020; 181 (2): 236–49
 - **Germline Testing for Patients With BRCA1/2 Mutations on Somatic Tumor Testing** *JNCI CANCER SPECTRUM*
Vlassis, K., Purington, N., Chun, N., Haraldsdottir, S., Ford, J. M.
2020; 4 (1): pkz095
 - **Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary Cancers.** *JCO precision oncology*
Maxwell, K. N., Wenz, B. M., Kulkarni, A., Wubbenhorst, B., D'Andrea, K., Weathers, B., Goodman, N., Vijai, J., Lilyquist, J., Hart, S. N., Slavin, T. P., Schrader, K. A., Ravichandran, et al
2020; 4
 - **One Step Further Toward Defining the Exceptional Cancer Responder.** *Journal of the National Cancer Institute*
Ford, J. M., Mitchell, B. S.
2020
 - **Prevalence of Lynch syndrome in women with mismatch repair-deficient ovarian cancer.** *Cancer medicine*
Hodan, R. n., Kingham, K. n., Cotter, K. n., Folkins, A. K., Kurian, A. W., Ford, J. M., Longacre, T. n.
2020
 - **NCI-MATCH EAY131-Z11: Phase II study of AZD1775, a wee-1 kinase inhibitor, in patients with tumors containing BRCA1 and BRCA2 mutations**
Kummar, S., Li, S., Reiss, K., Ford, J. M., Mitchell, E. P., Zwiebel, J. A., Takebe, N., Gray, R. J., McShane, L. M., Rubinstein, L. V., Patton, D., Williams, P., Hamilton, et al
AMER ASSOC CANCER RESEARCH.2019
 - **HAT1 Coordinates Histone Production and Acetylation via H4 Promoter Binding.** *Molecular cell*
Gruber, J. J., Geller, B., Lipchik, A. M., Chen, J., Salahudeen, A. A., Ram, A. N., Ford, J. M., Kuo, C. J., Snyder, M. P.
2019
 - **Association of Tumor Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Telli, M. L., Chu, C. n., Badve, S. S., Vinayak, S. n., Silver, D. P., Isakoff, S. J., Kaklamani, V. n., Gradishar, W. n., Stearns, V. n., Connolly, R. M., Ford, J. M., Gruber, J. J., Adams, et al
2019
 - **Genomics in medicine: a novel elective rotation for internal medicine residents.** *Postgraduate medical journal*
Geng, L. N., Kohler, J. N., Levonian, P. n., Bernstein, J. A., Ford, J. M., Ahuja, N. n., Witteles, R. n., Hom, J. n., Wheeler, M. n.
2019
 - **Chromatin Remodeling in Response to BRCA2-Crisis.** *Cell reports*
Gruber, J. J., Chen, J. n., Geller, B. n., Jäger, N. n., Lipchik, A. M., Wang, G. n., Kurian, A. W., Ford, J. M., Snyder, M. P.
2019; 28 (8): 2182–93.e6
 - **Comprehensive genomic characterization of breast tumors with BRCA1 and BRCA2 mutations.** *BMC medical genomics*
Lal, A. n., Ramazzotti, D. n., Weng, Z. n., Liu, K. n., Ford, J. M., Sidow, A. n.
2019; 12 (1): 84

- **High-Resolution Bisulfite-Sequencing of Peripheral Blood DNA Methylation in Early-Onset and Familial Risk Breast Cancer Patients.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Chen, J. n., Haanpää, M. K., Gruber, J. J., Jäger, N. n., Ford, J. M., Snyder, M. P.
2019
- **Increased MTH1-specific 8-oxodGTPase activity is a hallmark of cancer in colon, lung and pancreatic tissue.** *DNA repair*
McPherson, L. A., Troccoli, C. I., Ji, D. n., Bowles, A. E., Gardiner, M. L., Mohsen, M. G., Nagathihalli, N. S., Nguyen, D. M., Robbins, D. J., Merchant, N. B., Kool, E. T., Rai, P. n., Ford, et al
2019: 102644
- **Tumor Molecular Profiling Aids in Determining Tissue of Origin and Therapy for Metastatic Adenocarcinoma in a Patient With Multiple Primary Malignancies** *JCO PRECISION ONCOLOGY*
Costa, H. A., Reyes, R., Mills, M., Zehnder, J. L., Sledge, G., Curtis, C., Ford, J. M., Suarez, C. J.
2018; 2
- **Strategies For Clinical Implementation: Precision Oncology At Three Distinct Institutions** *HEALTH AFFAIRS*
Nadauld, L. D., Ford, J. M., Pritchard, D., Brown, T.
2018; 37 (5): 751–56
- **Precision oncology in advanced cancer patients improves overall survival with lower weekly healthcare costs.** *Oncotarget*
Haslem, D. S., Chakravarty, I., Fulde, G., Gilbert, H., Tudor, B. P., Lin, K., Ford, J. M., Nadauld, L. D.
2018; 9 (15): 12316–22
- **Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.** *Breast cancer research and treatment*
Telli, M. L., Hellyer, J. n., Audeh, W. n., Jensen, K. C., Bose, S. n., Timms, K. M., Gutin, A. n., Abkevich, V. n., Peterson, R. N., Neff, C. n., Hughes, E. n., Sangale, Z. n., Jones, et al
2018; 168 (3): 625–30
- **Totally Unexpected: Nonsyndromic CDH1 Mutations and Hereditary Diffuse Gastric Cancer Syndrome.** *JCO precision oncology*
Ford, J. M.
2017; 1: 1-2
- **IDH2 Mutation in a Patient with Metastatic Colon Cancer** *NEW ENGLAND JOURNAL OF MEDICINE*
Zhang, B. M., Zehnder, J. L., Suarez, C. J.
2017; 376 (20): 1991-1992
- **Poly (ADP-ribose) polymerase inhibitor, an effective radiosensitizer in lung and pancreatic cancers** *ONCOTARGET*
Hastak, K., Bhutra, S., Parry, R., Ford, J. M.
2017; 8 (16): 26344-26355
- **Tumor BRCA1 Reversion Mutation Arising During Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Afghahi, A., Timms, K. M., Vinayak, S., Jensen, K. C., Kurian, A. W., Carlson, R. W., Chang, P., Schackmann, E. A., Hartman, A., Ford, J. M., Telli, M. L.
2017
- **Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk.** *Genetics in medicine : official journal of the American College of Medical Genetics*
Caswell-Jin, J. L., Gupta, T. n., Hall, E. n., Petrovchich, I. M., Mills, M. A., Kingham, K. E., Koff, R. n., Chun, N. M., Levonian, P. n., Lebensohn, A. P., Ford, J. M., Kurian, A. W.
2017
- **Precision Oncology: A New Forum for an Emerging Field** *JCO PRECISION ONCOLOGY*
Ford, J. M.
2017; 1
- **A Retrospective Analysis of Precision Medicine Outcomes in Patients With Advanced Cancer Reveals Improved Progression-Free Survival Without Increased Health Care Costs.** *Journal of oncology practice*
Haslem, D. S., Van Norman, S. B., Fulde, G., Knighton, A. J., Belnap, T., Butler, A. M., Rhagunath, S., Newman, D., Gilbert, H., Tudor, B. P., Lin, K., Stone, G. R., Loughmiller, et al
2016

- **Precision genomic medicine improves clinical outcomes in advanced cancer patients**
Nadauld, L. D., Van Norman, B., Fulde, G., Newman, D., Butler, A., Tudor, B., Gilbert, H., Lin, K., Stone, G., Konde, A., Petrovchich, I., Ford, J. M., Haslem, et al
AMER ASSOC CANCER RESEARCH.2016
- **American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility.** *Journal of clinical oncology*
Robson, M. E., Bradbury, A. R., Arun, B., Domchek, S. M., Ford, J. M., Hampel, H. L., Lipkin, S. M., Syngal, S., Wollins, D. S., Lindor, N. M.
2015; 33 (31): 3660-3667
- **Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment** *JAMA ONCOLOGY*
Desmond, A., Kurian, A., Gabree, M., Mills, M. A., Anderson, M. J., Kobayashi, Y., Horick, N., Yang, S., Shannon, K. M., Tung, N., Ford, J., Lincoln, S. E., Ellisen, et al
2015; 1 (7): 943-951
- **American Gastroenterological Association Technical Review on the Diagnosis and Management of Lynch Syndrome.** *Gastroenterology*
Ladabaum, U., Ford, J. M., Martel, M., Barkun, A. N.
2015; 149 (3): 783-813 e20
- **Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.** *Journal of clinical oncology*
Telli, M. L., Jensen, K. C., Vinayak, S., Kurian, A. W., Lipson, J. A., Flaherty, P. J., Timms, K., Abkevich, V., Schackmann, E. A., Wapnir, I. L., Carlson, R. W., Chang, P., Sparano, et al
2015; 33 (17): 1895-1901
- **Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers** *JOURNAL OF MEDICAL GENETICS*
van der Post, R. S., Vogelaar, I. P., Carneiro, F., Guilford, P., Huntsman, D., Hoogerbrugge, N., Caldas, C., Schreiber, K. E., Hardwick, R. H., Ausems, M. G., Bardram, L., Benusiglio, P. R., Bisseling, et al
2015; 52 (6): 361-374
- **Multigene Panel Testing in Oncology Practice: How Should We Respond?** *JAMA oncology*
Kurian, A. W., Ford, J. M.
2015; 1 (3): 277-278
- **Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers** *CANCER DISCOVERY*
Watkins, J., Weekes, D., Shah, V., Gazinska, P., Joshi, S., Sidhu, B., Gillett, C., Pinder, S., Vanoli, F., Jasin, M., Mayrhofer, M., Isaksson, A., Cheang, et al
2015; 5 (5): 488-505
- **Multigene Panel Testing in Oncology Practice: How Should We Respond?** *JAMA Oncology*
Kurian, A. W., Ford, J. M.
2015; 1 (3): 277-278
- **Therapeutic Targeting of BRCA1-Mutated Breast Cancers with Agents That Activate DNA Repair** *CANCER RESEARCH*
Alli, E., Solow-Cordero, D., Casey, S. C., Ford, J. M.
2014; 74 (21): 6205-6215
- **Clinical Evaluation of a Multiple-Gene Sequencing Panel for Hereditary Cancer Risk Assessment** *JOURNAL OF CLINICAL ONCOLOGY*
Kurian, A. W., Hare, E. E., Mills, M. A., Kingham, K. E., McPherson, L., Whittmore, A. S., McGuire, V., Ladabaum, U., Kobayashi, Y., Lincoln, S. E., Cargill, M., Ford, J. M.
2014; 32 (19): 2001-2009
- **Clinical interpretation and implications of whole-genome sequencing.** *JAMA*
Dewey, F. E., Grove, M. E., Pan, C., Goldstein, B. A., Bernstein, J. A., Chaib, H., Merker, J. D., Goldfeder, R. L., Enns, G. M., David, S. P., Pakdaman, N., Ormond, K. E., Caleshu, et al
2014; 311 (10): 1035-1045
- **Poly (ADP-ribose) polymerase inhibitor LT-626: Sensitivity correlates with MRE11 mutations and synergizes with platinum and irinotecan in colorectal cancer cells** *CANCER LETTERS*
McPherson, L. A., Shen, Y., Ford, J. M.
2014; 343 (2): 217-223
- **Metastatic tumor evolution and organoid modeling implicate TGFBR2 as a cancer driver in diffuse gastric cancer.** *Genome biology*

- Nadauld, L. D., Garcia, S., Natsoulis, G., Bell, J. M., Miotke, L., Hopmans, E. S., Xu, H., Pai, R. K., Palm, C., Regan, J. F., Chen, H., Flaherty, P., Ootani, et al
2014; 15 (8): 428-?
- **Metastatic tumor evolution and organoid modeling implicate TGFBR2 as a cancer driver in diffuse gastric cancer** *GENOME BIOLOGY*
Nadauld, L. D., Garcia, S., Natsoulis, G., Bell, J. M., Miotke, L., Hopmans, E. S., Xu, H., Pai, R. K., Palm, C., Regan, J. F., Chen, H., Flaherty, P., Ootani, et al
2014; 15 (8)
 - **Molecular profiling of gastric cancer: toward personalized cancer medicine.** *Journal of clinical oncology*
Nadauld, L. D., Ford, J. M.
2013; 31 (7): 838-839
 - **Lupus Antibody Tops Cancer Cells** *SCIENCE TRANSLATIONAL MEDICINE*
Ford, J. M.
2012; 4 (157)
 - **Lynch Syndrome in Patients With Colorectal Cancer Finding the Needle in the Haystack** *JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION*
Ladabaum, U., Ford, J. M.
2012; 308 (15): 1581-1583
 - **Long-Term Survivors of Gastric Cancer: A California Population-Based Study** *JOURNAL OF CLINICAL ONCOLOGY*
Kunz, P. L., Gubens, M., Fisher, G. A., Ford, J. M., Lichtensztajn, D. Y., Clarke, C. A.
2012; 30 (28): 3507-3515
 - **Genetic Testing by Cancer Site Stomach** *CANCER JOURNAL*
Chun, N., Ford, J. M.
2012; 18 (4): 355-363
 - **Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomol** *DNA REPAIR*
Alli, E., Ford, J. M.
2012; 11 (5): 522-524
 - **Is breast cancer a part of Lynch syndrome?** *Breast cancer research : BCR*
Ford, J. M.
2012; 14 (4): 110
 - **Strategies to Identify the Lynch Syndrome Among Patients With Colorectal Cancer A Cost-Effectiveness Analysis** *ANNALS OF INTERNAL MEDICINE*
Ladabaum, U., Wang, G., Terdiman, J., Blanco, A., Kuppermann, M., Boland, C. R., Ford, J., Elkin, E., Phillips, K. A.
2011; 155 (2): 69-U50
 - **Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells.** *BMC pharmacology*
Alli, E., Sharma, V. B., Hartman, A., Lin, P. S., McPherson, L., Ford, J. M.
2011; 11: 7-?
 - **Synergistic Chemosensitivity of Triple-Negative Breast Cancer Cell Lines to Poly(ADP-Ribose) Polymerase Inhibition, Gemcitabine, and Cisplatin** *CANCER RESEARCH*
Hastak, K., Alli, E., Ford, J. M.
2010; 70 (20): 7970-7980
 - **Second Primary Breast Cancer Occurrence According to Hormone Receptor Status** *JOURNAL OF THE NATIONAL CANCER INSTITUTE*
Kurian, A. W., McClure, L. A., John, E. M., Horn-Ross, P. L., Ford, J. M., Clarke, C. A.
2009; 101 (15): 1058-1065
 - **Defective Repair of Oxidative DNA Damage in Triple-Negative Breast Cancer Confers Sensitivity to Inhibition of Poly(ADP-Ribose) Polymerase** *CANCER RESEARCH*
Alli, E., Sharma, V. B., Sunderesakumar, P., Ford, J. M.
2009; 69 (8): 3589-3596
 - **Performance of BRCA1/2 mutation prediction models in Asian Americans** *43rd Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)*
Kurian, A. W., Gong, G. D., Chun, N. M., Mills, M. A., Staton, A. D., Kingham, K. E., Crawford, B. B., Lee, R., Chan, S., Donlon, S. S., Ridge, Y., Panabaker, K., West, et al
AMER SOC CLINICAL ONCOLOGY.2008: 4752-58

- **Hereditary diffuse gastric cancer - Implications of genetic testing for screening and prophylactic surgery** *CANCER*
Cisco, R. M., Ford, J. M., Norton, J. A.
2008; 113 (7): 1850-1856
- **CDH1 truncating mutations in the E-cadherin gene - An indication for total gastrectomy to treat hereditary diffuse gastric cancer** *ANNALS OF SURGERY*
Norton, J. A., Ham, C. M., Van Dam, J., Jeffrey, R. B., Longacre, T. A., Huntsman, D. G., Chun, N., Kurian, A. W., Ford, J. M.
2007; 245 (6): 873-879
- **Predicting and preventing hereditary colorectal cancer** *JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION*
Ford, J. M., Whittemore, A. S.
2006; 296 (12): 1521-1523
- **Molecular inversion probe analysis of gene copy alterations reveals distinct categories of colorectal carcinoma** *CANCER RESEARCH*
Ji, H., Kumm, J., Zhang, M., Farnam, K., Salari, K., Faham, M., Ford, J. M., Davis, R. W.
2006; 66 (16): 7910-7919
- **Opposing effects of the UV lesion repair protein XPA and UV bypass polymerase eta on ATR checkpoint signaling** *EMBO JOURNAL*
D Bomgardner, R., Lupardus, P. J., Soni, D. V., Yee, M., Ford, J. M., Cimprich, K. A.
2006; 25 (11): 2605-2614
- **In vivo recruitment of XPC to UV-induced cyclobutane pyrimidine dimers by the DDB2 gene product** *JOURNAL OF BIOLOGICAL CHEMISTRY*
Fitch, M. E., Nakajima, S., Yasui, A., Ford, J. M.
2003; 278 (47): 46906-46910
- **p53 and regulation of DNA damage recognition during nucleotide excision repair** *DNA REPAIR*
Adimoolam, S., Ford, J. M.
2003; 2 (9): 947-954
- **The DDB2 nucleotide excision repair gene product p48 enhances global genomic repair in p53 deficient human fibroblasts** *DNA REPAIR*
Fitch, M. E., Cross, I. V., Turner, S. J., Adimoolam, S., Lin, C. X., Williams, K. G., Ford, J. A.
2003; 2 (7): 819-826
- **p53 responsive nucleotide excision repair gene products p48 and XPC, but not p53, localize to sites of UV-irradiation-induced DNA damage, in vivo** *CARCINOGENESIS*
Fitch, M. E., Cross, I. V., Ford, J. M.
2003; 24 (5): 843-850
- **p53 and DNA damage-inducible expression of the xeroderma pigmentosum group C gene** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Adimoolam, S., Ford, J. M.
2002; 99 (20): 12985-12990
- **BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair** *NATURE GENETICS*
Hartman, A. R., Ford, J. M.
2002; 32 (1): 180-184
- **Xeroderma pigmentosum p48 gene enhances global genomic repair and suppresses UV-induced mutagenesis** *MOLECULAR CELL*
Tang, J. Y., Hwang, B. J., Ford, J. M., Hanawalt, P. C., Chu, G.
2000; 5 (4): 737-744
- **Expression of the p48 xeroderma pigmentosum gene is p53-dependent and is involved in global genomic repair** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Hwang, B. J., Ford, J. M., Hanawalt, P. C., Chu, G.
1999; 96 (2): 424-428
- **Expression of wild-type p53 is required for efficient global genomic nucleotide excision repair in UV-irradiated human fibroblasts** *JOURNAL OF BIOLOGICAL CHEMISTRY*
Ford, J. M., Hanawalt, P. C.
1997; 272 (44): 28073-28080

- **LI-FRAUMENI SYNDROME FIBROBLASTS HOMOZYGOUS FOR P53 MUTATIONS ARE DEFICIENT IN GLOBAL DNA-REPAIR BUT EXHIBIT NORMAL TRANSCRIPTION-COUPLED REPAIR AND ENHANCED UV RESISTANCE** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Ford, J. M., Hanawalt, P. C.
1995; 92 (19): 8876-8880
- **Repurposing mebendazole against triple-negative breast cancer CNS metastasis.** *Journal of neuro-oncology*
Rodrigues, A. J., Chernikova, S. B., Wang, Y., Trinh, T. T., Solow-Cordero, D. E., Alexandrova, L., Casey, K. M., Alli, E., Aggarwal, A., Quill, T., Koegel, A. K., Feldman, B. J., Ford, et al
2024
- **Repurposing mebendazole against triple-negative breast cancer leptomeningeal disease.** *Research square*
Rodrigues, A., Chernikova, S. B., Wang, Y., Trinh, T. T., Solow-Cordero, D. E., Alexandrova, L., Casey, K. M., Alli, E., Aggarwal, A., Quill, T., Koegel, A., Feldman, B. J., Ford, et al
2024
- **Identification of a potential chemoprevention agent for BRCA1- mutated cancers**
Shanmugam, S., Hosch, E., Konar, D., Ford, J. M., Alli, E.
AMER ASSOC CANCER RESEARCH.2022
- **Identification of a potential chemoprevention agent for BRCA1- mutated cancers.**
Shanmugam, S., Hosch, E., Konar, D., Ford, J. M., Alli, E.
AMER ASSOC CANCER RESEARCH.2022
- **Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.** *Journal of the National Cancer Institute*
Rodriguez, C. P., Kang, H., Geiger, J. L., Burtness, B., Chung, C. H., Pickering, C. R., Fakhry, C., Le, Q. T., Yom, S. S., Galloway, T. J., Golemis, E., Li, A., Shoop, et al
2022
- **Targeting HER2 mutation-positive advanced biliary tract cancers with neratinib: Final results from the phase 2 SUMMIT basket trial.**
Harding, J. J., Piha-Paul, S., Shah, R. H., Cleary, J. M., Quinn, D. I., Brana, I., Moreno, V., Borad, M. J., Loi, S., Spanggaard, I., Ford, J. M., DiPrimeo, D., Berger, et al
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Exploring homologous recombination deficiency thresholds for predicting response to platinum-based treatment in triple negative breast cancer.**
Timms, K., Lenz, L., Cogan, E. S., Mayer, E. L., Kaklamani, V. G., Stearns, V., Abramson, V. G., Falkson, C., Jankowitz, R., Marcom, P., Tung, N. M., Gradishar, W., Ford, et al
LIPPINCOTT WILLIAMS & WILKINS.2022
- **MITI minimum information guidelines for highly multiplexed tissue images.** *Nature methods*
Schapiro, D., Yapp, C., Sokolov, A., Reynolds, S. M., Chen, Y., Sudar, D., Xie, Y., Muhlich, J., Arias-Camison, R., Arena, S., Taylor, A. J., Nikolov, M., Tyler, et al
2022; 19 (3): 262-267
- **Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I.** *JCO precision oncology*
Krop, I. E., Jegede, O. A., Grilley-Olson, J. E., Lauring, J. D., Mitchell, E. P., Zwiebel, J. A., Gray, R. J., Wang, V., McShane, L. M., Rubinstein, L. V., Patton, D., Williams, P. M., Hamilton, et al
2022; 6: e2100424
- **Surgery for Hereditary Diffuse Gastric Cancer: Long-Term Outcomes.** *Cancers*
Forrester, J. D., Foster, D., Ford, J. M., Longacre, T. A., Ladabaum, U., Fry, S., Norton, J. A.
2022; 14 (3)
- **Genomic analysis from the talazoparib beyond BRCA clinical trial: Homologous recombination (HR) deficiency scores, loss-of-heterozygosity and mutations in non-BRCA1/2 mutant tumors with other HR mutations**
Gruber, J. J., Afghahi, A., Hatton, A., Gross, W., Foran, J., McMillan, A., Ford, J. M., Telli, M. L.
AMER ASSOC CANCER RESEARCH.2021
- **Targeting HER2 (ERBB2) mutation-positive advanced biliary tract cancers with neratinib: Results from the phase II SUMMIT 'basket' trial.**

- Harding, J. J., Cleary, J. M., Quinn, D. I., Brana, I., Moreno, V., Borad, M. J., Loi, S., Spanggaard, I., Park, H., Ford, J. M., Arnedos, M., Stemmer, S. M., De La Fouchardiere, et al
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Subtle endoscopic manifestations of diffuse signet cell gastric adenocarcinoma in patients with CDH1 mutations.** *Gastrointestinal endoscopy*
Ladabaum, U., Ford, J. M., Poultsides, G., Norton, J.
2021
 - **A novel DDB2 mutation causes defective recognition of UV-induced DNA damages and prevalent equine squamous cell carcinoma.** *DNA repair*
Chen, L., Bellone, R. R., Wang, Y., Singer-Berk, M., Sugasawa, K., Ford, J. M., Artandi, S. E.
2020; 97: 103022
 - **Universal Screening of Gastrointestinal Malignancies for Mismatch Repair Deficiency at Stanford.** *JNCI cancer spectrum*
Abrha, A., Shukla, N. D., Hodan, R., Longacre, T., Raghavan, S., Pritchard, C. C., Fisher, G., Ford, J., Haraldsdottir, S.
2020; 4 (5): pkaa054
 - **Clinicopathologic features of invasive breast cancer (BC) diagnosed in carriers of germline PALB2, CHEK2 and ATM pathogenic variants.**
Scott, D., Kingham, K., Hodan, R., Ma, C., Mills, M., Ford, J. M., Kurian, A. W., Telli, M. L.
AMER SOC CLINICAL ONCOLOGY.2020
 - **Germline mutation in 1,338 BRCA-negative Chinese hereditary breast and/or ovarian cancer patients: clinical testing with a multigene test panel.** *The Journal of molecular diagnostics : JMD*
Kwong, A., Shin, V. Y., Chen, J., Wai-Yin Cheuk, I., Ho, C. Y., Au, C. H., Chan, K. K., Ngan, H. Y., Chan, T. L., Ford, J. M., Ma, E. S.
2020
 - **Gastric Cancer Registry: A comprehensive patient-reported resource for multidisciplinary and translational genomic approaches to gastric cancer**
Almeda, A., Hooker, A., Lee, H., Mills, M., Van Hummelen, P., Ford, J. M., Ji, H.
AMER SOC CLINICAL ONCOLOGY.2020
 - **Statistical Methods in Precision Oncology.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Lu, Y. n., Lee, J. J., Ford, J. M.
2020: JCO1903173
 - **Whole genome analysis identifies the association of TP53 genomic deletions with lower survival in Stage III colorectal cancer.** *Scientific reports*
Xia, L. C., Van Hummelen, P. n., Kubit, M. n., Lee, H. n., Bell, J. M., Grimes, S. M., Wood-Bouwens, C. n., Greer, S. U., Barker, T. n., Haslem, D. S., Ford, J. M., Fulde, G. n., Ji, et al
2020; 10 (1): 5009
 - **A novel DDB2 mutation causes defective recognition of UV-induced DNA damages and prevalent equine squamous cell carcinoma** *DNA Repair*
Chen, L., Bellone, R. R., Wang, Y., Singer-Berk, M., Sugasawa, K., Ford, J. M., Artandi, S. E.
2020
 - **Psychosocial outcomes following germline multigene panel testing in an ethnically and economically diverse cohort of patients.** *Cancer*
Culver, J. O., Ricker, C. N., Bonner, J. n., Kidd, J. n., Sturgeon, D. n., Hodan, R. n., Kingham, K. n., Lowstuter, K. n., Chun, N. M., Lebensohn, A. P., Rowe-Teeter, C. n., Levonian, P. n., Partynski, et al
2020
 - **Clinical Outcome Event Adjudication in a 10-Year Prospective Study of Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B.** *Journal of clinical and translational hepatology*
Lim, J. K., Chang, A. Y., Zaman, A. n., Martin, P. n., Fernandez-Rodriguez, C. M., Korkmaz, M. n., Rossi, S. n., Ford, J. M., Noonan, T. n., Cooney, E. n., Navarro, V. n., Colombato, L. n.
2020; 8 (4): 377-84
 - **Talazoparib beyond BRCA: A phase II trial of talazoparib monotherapy in BRCA1 and BRCA2 wild-type patients with advanced HER2-negative breast cancer or other solid tumors with a mutation in homologous recombination (HR) pathway genes.**
Gruber, J., Afghahi, A., Hatton, A., Scott, D., McMillan, A., Ford, J. M., Telli, M. L.
AMER SOC CLINICAL ONCOLOGY.2019
 - **Preventive surgery after multiplex genetic panel testing (MGPT)**
Idos, G., Kurian, A. W., Ricker, C., Sturgeon, D., Culver, J., Kingham, K., Koff, R., Chun, N. M., Rowe-Teeter, C., Levonian, P., Hong, C., Mills, M., Ma, et al
AMER SOC CLINICAL ONCOLOGY.2019

- **JAVELIN BRCA/ATM: A phase 2 trial of avelumab (anti-PD-L1) plus talazoparib (PARP inhibitor) in patients with advanced solid tumors with a BRCA1/2 or ATM defect.**
Hyman, D., Zelnak, A. B., Bauer, T., Ulahannan, S., Ford, J. M., Cesari, R., Hoyle, M., Chappey, C., Stewart, R., Conte, U., Yap, T. A.
AMER SOC CLINICAL ONCOLOGY.2019
- **Clinical and pathological features of breast cancer among men and women with ATM and CDH1 mutations**
Tsang, A., Kingham, K., Kurian, A., Ford, J., Wapnir, I.
SPRINGER.2019: 69–70
- **Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk. *JCO precision oncology***
Idos, G. E., Kurian, A. W., Ricker, C., Sturgeon, D., Culver, J. O., Kingham, K. E., Koff, R., Chun, N. M., Rowe-Teeter, C., Lebensohn, A. P., Levonian, P., Lowstuter, K., Partynski, et al
2019; 3
- **Prevalence and molecular etiology of mismatch repair deficiency among gastrointestinal cancers.**
Shukla, N., Abrha, A., Longacre, T. A., Koff, R., Ford, J. M., Fisher, G. A., Haraldsdottir, S.
AMER SOC CLINICAL ONCOLOGY.2019
- **Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk *JCO Precision Oncology***
Idos, G. E., Kurian, A. W., Ricker, C., Sturgeon, D., Culver, J. O., Kingham, K. E., Koff, R., Chun, N. M., Rowe-Teeter, C., Lebensohn, A. P., Levonian, P., Lowstuter, K., Partynski, et al
2019
- **Tumor Molecular Profiling Aids in Determining Tissue of Origin and Therapy for Metastatic Adenocarcinoma in a Patient With Multiple Primary Malignancies. *JCO precision oncology***
Costa, H. A., Reyes, R., Mills, M., Zehnder, J. L., Sledge, G., Curtis, C., Ford, J. M., Suarez, C. J.
2018; 2: 1-4
- **Introducing the JCO Precision Oncology Molecular Tumor Board Case Discussion Series. *JCO precision oncology***
Ford, J. M.
2018; 2: 1
- **Delivering Precision Oncology in a Community Cancer Program: Results From a Prospective Observational Study. *JCO precision oncology***
Powell, S. F., Dib, E. G., Bleeker, J. S., Keppen, M. D., Mazurczak, M., Hack, K. M., Gitau, M. M., Steen, P. D., Terstriep, S. A., Reynolds, J., Landsverk, M. L., Chan, C. H., Nelson, et al
2018; 2: 1-12
- **Pathogenic Variants in Less Familiar Cancer Susceptibility Genes: What Happens After Genetic Testing? *JCO precision oncology***
Hall, E. T., Parikh, D., Caswell-Jin, J. L., Gupta, T., Mills, M. A., Kingham, K. E., Koff, R., Ford, J. M., Kurian, A. W.
2018; 2: 1-10
- **Surgical and molecular characterization of primary and metastatic disease in a neuroendocrine tumor arising in a tailgut cyst *COLD SPRING HARBOR MOLECULAR CASE STUDIES***
Erdrich, J., Schaberg, K. B., Khodadoust, M. S., Zhou, L., Shelton, A. A., Visser, B. C., Ford, J. M., Alizadeh, A. A., Quake, S. R., Kunz, P. L., Beausang, J. F.
2018; 4 (5)
- **From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing. *Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research***
Trosman, J. R., Weldon, C. B., Gradishar, W. J., Benson, A. B., Cristofanilli, M., Kurian, A. W., Ford, J. M., Balch, A., Watkins, J., Phillips, K. A.
2018; 21 (9): 1062-1068
- **Small molecules facilitating DNA repair in breast cancer cells**
Pandrala, M., Hastak, K., Kumar, V., Gardiner, M., Ford, J., Malhotra, S.
AMER CHEMICAL SOC.2018
- **Surgical and molecular characterization of primary and metastatic disease in a neuroendocrine tumor arising in a tailgut cyst. *Cold Spring Harbor molecular case studies***
Erdrich, J., Schaberg, K., Khodadoust, M. S., Zhou, L., Shelton, A. A., Visser, B. C., Ford, J. M., Alizadeh, A. A., Quake, S. R., Kunz, P. L., Beausang, J. F.
2018

- **NCCN Guidelines Insights: Colorectal Cancer Screening, Version 1.2018.** *Journal of the National Comprehensive Cancer Network : JNCCN*
Provenzale, D., Gupta, S., Ahnen, D. J., Markowitz, A. J., Chung, D. C., Mayer, R. J., Regenberg, S. E., Blanco, A. M., Bray, T., Cooper, G., Early, D. S., Ford, J. M., Giardiello, et al
2018; 16 (8): 939–49
- **VISTA immune checkpoint deregulation in human triple-negative breast cancer**
Gruber, J. J., Juntilla, M. M., Yang, S., Geller, B., Jager, N., Lin, C., Lipchik, A. M., Chen, J., Ram, A., Vinayak, S., Telli, M. L., West, R. B., Ford, et al
AMER ASSOC CANCER RESEARCH.2018
- **Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer** *CLINICAL CANCER RESEARCH*
Afghahi, A., Purington, N., Han, S. S., Desai, M., Pierson, E., Mathur, M. B., Seto, T., Thompson, C. A., Rigdon, J., Telli, M. L., Badve, S. S., Curtis, C. N., West, et al
2018; 24 (12): 2851–58
- **Promoting colorectal cancer (CRC) screening after multiplex genetic testing and genetic counseling**
Idos, G., Kurian, A. W., Ricker, C., Sturgeon, D., Culver, J., Kingham, K., Koff, R., Chun, N. M., Rowe-Teeter, C., Kidd, J., Evans, B., Brown, K., Mills, et al
AMER SOC CLINICAL ONCOLOGY.2018
- **Promoting breast cancer screening after multiplex genetic panel testing (MGPT) and genetic counseling**
Idos, G., Kurian, A. W., Ricker, C., Sturgeon, D., Culver, J., Kingham, K., Koff, R., Chun, N. M., Rowe-Teeter, C., Kidd, J., Evans, B., Brown, K., Mills, et al
AMER SOC CLINICAL ONCOLOGY.2018
- **Delivering Precision Oncology in a Community Cancer Program: Results From a Prospective Observational Study** *JCO PRECISION ONCOLOGY*
Powell, S. E., Dib, E. G., Bleeker, J. S., Keppen, M. D., Mazurczak, M., Hack, K. M., Gitau, M. M., Steen, P. D., Terstriep, S. A., Reynolds, J., Landsverk, M. L., Chan, C., Nelson, et al
2018; 2: 1–12
- **Molecular Characterization of Aggressive Estrogen Receptor Positive Breast Cancer Resistant to Palbociclib Therapy**
Lei, L., Lin, C., Steiner, D., Ford, J. M., Zehnder, J. L., Suarez, C. J.
NATURE PUBLISHING GROUP.2018: 703
- **Molecular Characterization of Aggressive Estrogen Receptor Positive Breast Cancer Resistant to Palbociclib Therapy**
Lei, L., Lin, C., Steiner, D., Ford, J. M., Zehnder, J. L., Suarez, C. J.
NATURE PUBLISHING GROUP.2018: 703
- **Introducing the JCO Precision Oncology Molecular Tumor Board Case Discussion Series** *JCO PRECISION ONCOLOGY*
Ford, J. M.
2018; 2
- **Patient communication of cancer genetic test results in a diverse population.** *Translational behavioral medicine*
Ricker, C. N., Koff, R. B., Qu, C. n., Culver, J. n., Sturgeon, D. n., Kingham, K. E., Lowstuter, K. n., Chun, N. M., Rowe-Teeter, C. n., Lebensohn, A. n., Levonian, P. n., Partynski, K. n., Lara-Otero, et al
2018; 8 (1): 85–94
- **Pathogenic variants in less familiar cancer susceptibility genes: what happens after genetic testing?** *JCO Precision Oncology*
Hall, E. T., Parikh, D., Caswell-Jin, J. L., Gupta, T., Mills, M. A., Kingham, K. E., Koff, R., Ford, J. M., Kurian, A. W.
2018
- **Rapid detection ofBRCA1/2recurrent mutations in Chinese breast and ovarian cancer patients with multiplex SNaPshot genotyping panels.** *Oncotarget*
Kwong, A. n., Ho, J. C., Shin, V. Y., Kurian, A. W., Tai, E. n., Esserman, L. J., Weitzel, J. N., Lin, P. H., Field, M. n., Domchek, S. M., Lo, J. n., Ngan, H. Y., Ma, et al
2018; 9 (8): 7832–43
- **From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing** *Value in Health*
Trosman, J. R., Weldon, C. B., Gradishar, W. J., Benson, A. B., Cristofanilli, M., Kurian, A. W., Ford, J. M., Balch, A., Watkins, J., Phillips, K. A.
2018: 1062-1068
- **Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Afghahi, A. n., Purington, N. n., Han, S. S., Desai, M. n., Pierson, E. n., Mathur, M. B., Seto, T. n., Thompson, C. A., Rigdon, J. n., Telli, M. L., Badve, S. S., Curtis, C. n., West, et al

2018

- **NCCN Guidelines (R) Insights Genetic/Familial High-Risk Assessment: Colorectal, Version 3.2017 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Gupta, S., Provenzale, D., Regenberg, S. E., Hampel, H., Slavin, T. P., Hall, M. J., Llor, X., Chung, D. C., Ahnen, D. J., Bray, T., Cooper, G., Early, D. S., Ford, et al
2017; 15 (12): 1465–74
- **The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk (vol 3, 22, 2017)** *NPJ BREAST CANCER*
Slavin, T. P., Maxwell, K. N., Lilyquist, J., Vijai, J., Neuhausen, S. L., Hart, S. N., Ravichandran, V., Thomas, T., Maria, A., Villano, D., Schrader, K. A., Moore, R., Hu, et al
2017; 3: 44
- **Precision Oncology Strategy in Trastuzumab-Resistant Human Epidermal Growth Factor Receptor 2-Positive Colon Cancer: Case Report of Durable Response to Ado-Trastuzumab Emtansine.** *JCO precision oncology*
Haslem, D. S., Ji, H. P., Ford, J. M., Nadauld, L. D.
2017; 1
- **The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk** *NPJ BREAST CANCER*
Slavin, T. P., Maxwell, K. N., Lilyquist, J., Vijai, J., Neuhausen, S. L., Hart, S. N., Ravichandran, V., Thomas, T., Maria, A., Villano, D., Schrader, K. A., Moore, R., Hu, et al
2017; 3: 22
- **Molecular receptor profiles in male mutation carriers with breast cancer**
Wapnir, I., Kingham, K., Mills, M., Ford, J., Kurian, A.
SPRINGER.2017: 112–13
- **Long-read genome sequencing identifies causal structural variation in a Mendelian disease.** *Genetics in medicine : official journal of the American College of Medical Genetics*
Merker, J. D., Wenger, A. M., Sneddon, T. n., Grove, M. n., Zappala, Z. n., Fresard, L. n., Waggott, D. n., Utiramerur, S. n., Hou, Y. n., Smith, K. S., Montgomery, S. B., Wheeler, M. n., Buchan, et al
2017
- **Precision Oncology: A New Forum for an Emerging Field.** *JCO precision oncology*
Ford, J. M.
2017; 1: 1-2
- **Precision Oncology Strategy in Trastuzumab-Resistant Human Epidermal Growth Factor Receptor 2-Positive Colon Cancer: Case Report of Durable Response to Ado-Trastuzumab Emtansine** *JCO PRECISION ONCOLOGY*
Haslem, D. S., Ji, H. P., Ford, J. M., Nadauld, L. D.
2017; 1
- **Linked read sequencing resolves complex genomic rearrangements in gastric cancer metastases.** *Genome medicine*
Greer, S. U., Nadauld, L. D., Lau, B. T., Chen, J. n., Wood-Bouwens, C. n., Ford, J. M., Kuo, C. J., Ji, H. P.
2017; 9 (1): 57
- **Interferon-beta represses cancer stem cell properties in triple-negative breast cancer.** *Proceedings of the National Academy of Sciences of the United States of America*
Doherty, M. R., Cheon, H. n., Junk, D. J., Vinayak, S. n., Varadan, V. n., Telli, M. L., Ford, J. M., Stark, G. R., Jackson, M. W.
2017; 114 (52): 13792–97
- **Genetic predisposition to gastric cancer** *SEMINARS IN ONCOLOGY*
Petrovchich, I., Ford, J. M.
2016; 43 (5): 554-559
- **Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.** *Clinical cancer research*
Telli, M. L., Timms, K. M., Reid, J., Hennessy, B., Mills, G. B., Jensen, K. C., Szallasi, Z., Barry, W. T., Winer, E. P., Tung, N. M., Isakoff, S. J., Ryan, P. D., Greene-Colozzi, et al
2016; 22 (15): 3764-3773

- **Genetic/Familial High-Risk Assessment: Colorectal Version 1.2016** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Provenzale, D., Gupta, S., Ahnen, D. J., Bray, T., Cannon, J. A., Cooper, G., David, D. S., Early, D. S., Erwin, D., Ford, J. M., Giardiello, F. M., Grady, W., Halverson, et al
2016; 14 (8): 1010-1030
- **A Chimeric ATP-Linked Nucleotide Enables Luminescence Signaling of Damage Surveillance by MTH1, a Cancer Target.** *Journal of the American Chemical Society*
Ji, D., Beharry, A. A., Ford, J. M., Kool, E. T.
2016; 138 (29): 9005-9008
- **Detection of Germline Mutation in Hereditary Breast and/or Ovarian Cancers by Next-Generation Sequencing on a Four-Gene Panel** *JOURNAL OF MOLECULAR DIAGNOSTICS*
Kwong, A., Shin, V. Y., Au, C. H., Law, F. B., Ho, D. N., Ip, B. K., Wong, A. T., Lau, S. S., To, R. M., Choy, G., Ford, J. M., Ma, E. S., Chan, et al
2016; 18 (4): 580-594
- **DNA-repair defects in pancreatic neuroendocrine tumors and potential clinical applications** *CANCER TREATMENT REVIEWS*
Liu, I. H., Ford, J. M., Kunz, P. L.
2016; 44: 1-9
- **DNA-repair defects in pancreatic neuroendocrine tumors and potential clinical applications.** *Cancer treatment reviews*
Liu, I. H., Ford, J. M., Kunz, P. L.
2016; 44: 1-9
- **Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries** *JOURNAL OF MEDICAL GENETICS*
Kwong, A., Shin, V. Y., Ho, J. C., Kang, E., Nakamura, S., Teo, S., Lee, A. S., Sng, J., Ginsburg, O. M., Kurian, A. W., Weitzel, J. N., Siu, M., Law, et al
2016; 53 (1): 15-23
- **Discovery and functional characterization of a neomorphic PTEN mutation** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Costa, H. A., Leitner, M. G., Sos, M. L., Mavrantoni, A., Rychkova, A., Johnson, J. R., Newton, B. W., Yee, M., De La Vega, F. M., Ford, J. M., Krogan, N. J., Shokat, K. M., Oliver, et al
2015; 112 (45): 13976-13981
- **Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.** *JAMA oncology*
Desmond, A., Kurian, A. W., Gabree, M., Mills, M. A., Anderson, M. J., Kobayashi, Y., Horick, N., Yang, S., Shannon, K. M., Tung, N., Ford, J. M., Lincoln, S. E., Ellisen, et al
2015; 1 (7): 943-951
- **American Gastroenterological Association Technical Review on the Diagnosis and Management of Lynch Syndrome** *GASTROENTEROLOGY*
Ladabaum, U., Ford, J. M., Martel, M., Barkun, A. N.
2015; 149 (3): 783-?
- **The importance of analysis of long-range rearrangement of BRCA1 and BRCA2 in genetic diagnosis of familial breast cancer** *CANCER GENETICS*
Kwong, A., Chen, J., Shin, V. Y., Ho, J. C., Law, F. B., Au, C. H., Chan, T., Ma, E. S., Ford, J. M.
2015; 208 (9): 448-454
- **A Systematic Comparison of Traditional and Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Genes in More Than 1000 Patients** *JOURNAL OF MOLECULAR DIAGNOSTICS*
Lincoln, S. E., Kobayashi, Y., Anderson, M. J., Yang, S., Desmond, A. J., Mills, M. A., Nilsen, G. B., Jacobs, K. B., Monzon, F. A., Kurian, A. W., Ford, J. M., Ellisen, L. W.
2015; 17 (5): 533-544
- **BRCA1: Beyond double-strand break repair** *DNA REPAIR*
Alli, E., Ford, J. M.
2015; 32: 165-171
- **Colorectal Cancer Screening, Version 1.2015 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Provenzale, D., Jasperson, K., Ahnen, D. J., Aslanian, H., Bray, T., Cannon, J. A., David, D. S., Early, D. S., Erwin, D., Ford, J. M., Giardiello, F. M., Gupta, S., Halverson, et al
2015; 13 (8): 959-968

- **Colorectal Cancer Screening, Version 1.2015.** *Journal of the National Comprehensive Cancer Network*
Provenzale, D., Jasperson, K., Ahnen, D. J., Aslanian, H., Bray, T., Cannon, J. A., David, D. S., Early, D. S., Erwin, D., Ford, J. M., Giardiello, F. M., Gupta, S., Halverson, et al
2015; 13 (8): 959-968
- **BRCA1: a movement toward cancer prevention.** *Molecular & cellular oncology*
Alli, E., Ford, J. M.
2015; 2 (3)
- **Deconvoluting immune cell populations using 'in silico flow cytometry' with CIBERSORT: Association with neoadjuvant therapy response and genomic instability in TNBC**
Vinayak, S., Newman, A., Adams, S., Afghahi, A., Jensen, K. C., Badve, S. S., Ford, J. M., Alizadeh, A. A., Telli, M. L.
AMER ASSOC CANCER RESEARCH.2015
- **Hereditary Gastric Cancer An Update at 15 Years** *JAMA ONCOLOGY*
Ford, J. M.
2015; 1 (1): 16-18
- **DNA-Repair Defects in Pancreatic Neuroendocrine Tumors and Potential Clinical Applications**
Liu, I. H., Ford, J. M., Kunz, P. L.
LIPPINCOTT WILLIAMS & WILKINS.2015: 355
- **Next-generation sequencing for hereditary breast and gynecologic cancer risk assessment.** *Current opinion in obstetrics & gynecology*
Kurian, A. W., Kingham, K. E., Ford, J. M.
2015; 27 (1): 23-33
- **Lynch Syndrome Screening: Discordance in MMR and Germline Test Results**
Mafnas, C., Martin, B., Ford, J., Longacre, T.
NATURE PUBLISHING GROUP.2015: 177A
- **Lynch Syndrome Screening: Discordance in MMR and Germline Test Results**
Mafnas, C., Martin, B., Ford, J., Longacre, T.
NATURE PUBLISHING GROUP.2015: 177A
- **Metastatic Lobular Breast Carcinoma Mimicking Primary Signet Ring Adenocarcinoma in a Patient With a Suspected CDH1 Mutation** *JOURNAL OF CLINICAL ONCOLOGY*
Mahmud, N., Ford, J. M., Longacre, T. A., Parent, R., Norton, J. A.
2015; 33 (4): E19-E21
- **Metastatic lobular breast carcinoma mimicking primary signet ring adenocarcinoma in a patient with a suspected CDH1 mutation.** *Journal of clinical oncology*
Mahmud, N., Ford, J. M., Longacre, T. A., Parent, R., Norton, J. A.
2015; 33 (4): e19-21
- **Parent Decision-Making Around the Genetic Testing of Children for Germline TP53 Mutations** *CANCER*
Alderfer, M. A., Zelle, K., Lindell, R. B., Novokmet, A., Mai, P. L., Garber, J. E., Nathan, D., Scollon, S., Chun, N. M., Patenaude, A. F., Ford, J. M., Plon, S. E., Schiffman, et al
2015; 121 (2): 286-293
- **Multiple-Gene Panels and the Future of Genetic Testing** *Current Breast Cancer Reports*
Kurian, A. W., Ford, J. M.
2015
- **Single-versus Multifraction Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma: Outcomes and Toxicity** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Pollom, E. L., Alagappan, M., von Eyben, R., Kunz, P. L., Fisher, G. A., Ford, J. A., Poultsides, G. A., Visser, B. C., Norton, J. A., Kamaya, A., Cox, V. L., Columbo, L. A., Koong, et al
2014; 90 (4): 918-925
- **Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity.** *International journal of radiation oncology, biology, physics*

- Pollom, E. L., Alagappan, M., von Eyben, R., Kunz, P. L., Fisher, G. A., Ford, J. A., Poultsides, G. A., Visser, B. C., Norton, J. A., Kamaya, A., Cox, V. L., Columbo, L. A., Koong, et al
2014; 90 (4): 918-925
- **Lynch Syndrome Screening Should Be Considered for All Patients With Newly Diagnosed Endometrial Cancer** *AMERICAN JOURNAL OF SURGICAL PATHOLOGY*
Mills, A. M., Liou, S., Ford, J. M., Berek, J. S., Pai, R. K., Longacre, T. A.
2014; 38 (11): 1501-1509
 - **Association of increased tumor-infiltrating lymphocytes (TILs) with immunomodulatory (IM) triple-negative breast cancer (TNBC) subtype and response to neoadjuvant platinum-based therapy in PrECOG0105.**
Vinayak, S., Gray, R., Adams, S., Jensen, K. C., Manola, J., Afghahi, A., Goldstein, L. J., Ford, J. M., Badve, S. S., Telli, M. L.
AMER SOC CLINICAL ONCOLOGY.2014
 - **The MLH1 c.-27C>A and c.85G>T variants are linked to dominantly inherited MLH1 epimutation and are borne on a European ancestral haplotype.** *European journal of human genetics*
Kwok, C., Vogelaar, I. P., van Zelst-Stams, W. A., Mensenkamp, A. R., Ligtenberg, M. J., Rapkins, R. W., Ward, R. L., Chun, N., Ford, J. M., Ladabaum, U., McKinnon, W. C., Greenblatt, M. S., Hitchins, et al
2014; 22 (5): 617-624
 - **Clinical interpretation and implications of whole-genome sequencing.** *JAMA : the journal of the American Medical Association*
Dewey, F. E., Grove, M. E., Pan, C., Goldstein, B. A., Bernstein, J. A., Chaib, H., Merker, J. D., Goldfeder, R. L., Enns, G. M., David, S. P., Pakdaman, N., Ormond, K. E., Caleshu, et al
2014; 311 (10): 1035-1045
 - **American society of clinical oncology expert statement: collection and use of a cancer family history for oncology providers.** *Journal of clinical oncology*
Lu, K. H., Wood, M. E., Daniels, M., Burke, C., Ford, J., Kauff, N. D., Kohlmann, W., Lindor, N. M., Mulvey, T. M., Robinson, L., Rubinstein, W. S., Stoffel, E. M., Snyder, et al
2014; 32 (8): 833-840
 - **American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers.** *Journal of clinical oncology*
Lu, K. H., Wood, M. E., Daniels, M., Burke, C., Ford, J., Kauff, N. D., Kohlmann, W., Lindor, N. M., Mulvey, T. M., Robinson, L., Rubinstein, W. S., Stoffel, E. M., Snyder, et al
2014; 32 (8): 833-840
 - **Colorectal Cancer Screening Clinical Practice Guidelines in Oncology** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Burt, R. W., Cannon, J. A., David, D. S., Early, D. S., Ford, J. M., Giardiello, F. M., Halverson, A. L., Hamilton, S. R., Hampel, H., Ismail, M. K., Jasperson, K., Klapman, J. B., Lazenby, et al
2013; 11 (12): 1538-1575
 - **Colorectal cancer screening.** *Journal of the National Comprehensive Cancer Network*
Burt, R. W., Cannon, J. A., David, D. S., Early, D. S., Ford, J. M., Giardiello, F. M., Halverson, A. L., Hamilton, S. R., Hampel, H., Ismail, M. K., Jasperson, K., Klapman, J. B., Lazenby, et al
2013; 11 (12): 1538-1575
 - **Dynamic contrast-enhanced MRI-based biomarkers of therapeutic response in triple-negative breast cancer.** *Journal of the American Medical Association*
Golden, D. I., Lipson, J. A., Telli, M. L., Ford, J. M., Rubin, D. L.
2013; 20 (6): 1059-1066
 - **A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk.** *Breast cancer research and treatment*
Vinayak, S., Schwartz, E. J., Jensen, K., Lipson, J., Alli, E., McPherson, L., Fernandez, A. M., Sharma, V. B., Staton, A., Mills, M. A., Schackmann, E. A., Telli, M. L., Kardashian, et al
2013; 142 (2): 389-398
 - **A young woman with bilateral breast cancer: identifying a genetic cause and implications for management.** *Journal of the National Comprehensive Cancer Network*
de Bruin, M. A., Ford, J. M., Kurian, A. W.
2013; 11 (5): 512-517
 - **Seventh Edition (2010) of the AJCC/UICC Staging System for Gastric Adenocarcinoma: Is there Room for Improvement?** *ANNALS OF SURGICAL ONCOLOGY*

Patel, M. I., Rhoads, K. F., Ma, Y., Ford, J. M., Visser, B. C., Kunz, P. L., Fisher, G. A., Chang, D. T., Koong, A., Norton, J. A., Poultsides, G. A.
2013; 20 (5): 1631-1638

- **Male Breast Cancer: A Comparison Between BRCA Mutation Carriers and Noncarriers in Hong Kong, Southern China**
Kwong, A., Chau, W., Law, F. F., Kurian, A., Ford, J. M., West, D. W., Ma, E. K.
SPRINGER.2013: 72
- **Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer** *PLOS ONE*
Shah, M. A., Wainberg, Z. A., Catenacci, D. V., Hochster, H. S., Ford, J., Kunz, P., Lee, F., Kallender, H., Cecchi, F., Rabe, D. C., Keer, H., Martin, A., Liu, et al
2013; 8 (3)
- **Qualitative and quantitative image-based biomarkers of therapeutic response in triple-negative breast cancer.** *AMIA Summits on Translational Science proceedings AMIA Summit on Translational Science*
Golden, D. I., Lipson, J. A., Telli, M. L., Ford, J. M., Rubin, D. L.
2013; 2013: 62-?
- **Novel BRCA1 and BRCA2 genomic rearrangements in Southern Chinese breast/ovarian cancer patients** *BREAST CANCER RESEARCH AND TREATMENT*
Kwong, A., Ng, E. K., Law, F. B., Wong, H. N., Wa, A., Wong, C. L., Kurian, A. W., West, D. W., Ford, J. M., Ma, E. S.
2012; 136 (3): 931-933
- **Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium** *CANCER GENETICS*
Mai, P. L., Malkin, D., Garber, J. E., Schiffman, J. D., Weitzel, J. N., Strong, L. C., Wyss, O., Locke, L., Means, V., Achatz, M. I., Hainaut, P., Frebourg, T., Evans, et al
2012; 205 (10): 479-487
- **Identification of BRCA1/2 Founder Mutations in Southern Chinese Breast Cancer Patients Using Gene Sequencing and High Resolution DNA Melting Analysis** *PLOS ONE*
Kwong, A., Ng, E. K., Wong, C. L., Law, F. B., Au, T., Wong, H. N., Kurian, A. W., West, D. W., Ford, J. M., Ma, E. S.
2012; 7 (9)
- **Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations** *FAMILIAL CANCER*
de Bruin, M. A., Kwong, A., Goldstein, B. A., Lipson, J. A., Ikeda, D. M., McPherson, L., Sharma, B., Kardashian, A., Schackmann, E., Kingham, K. E., Mills, M. A., West, D. W., Ford, et al
2012; 11 (3): 429-439
- **Chest Wall Leiomyosarcoma After Breast-Conservative Therapy for Early-Stage Breast Cancer in a Young Woman With Li-Fraumeni Syndrome** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Henry, E., Villalobos, V., Million, L., Jensen, K. C., West, R., Ganjoo, K., Lebensohn, A., Ford, J. M., Telli, M. L.
2012; 10 (8): 939-942
- **Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features** *MODERN PATHOLOGY*
Chang, D. T., Pai, R. K., Rybicki, L. A., DiMaio, M. A., Limaye, M., Jayachandran, P., Koong, A. C., Kunz, P. A., Fisher, G. A., Ford, J. M., Welton, M., Shelton, A., Ma, et al
2012; 25 (8): 1128-1139
- **Identification of a novel deletion mutant strain in *Saccharomyces cerevisiae* that results in a microsatellite instability phenotype.** *BioDiscovery*
Ji, H. P., Morales, S., Welch, K., Yuen, C., Farnam, K., Ford, J. M.
2012
- **Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort** *BREAST CANCER RESEARCH AND TREATMENT*
Masciari, S., Dillon, D. A., Rath, M., Robson, M., Weitzel, J. N., Balmana, J., Gruber, S. B., Ford, J. M., Euhus, D., Lebensohn, A., Telli, M., Pochebit, S. M., Lypas, et al
2012; 133 (3): 1125-1130
- **Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell Lines** *PLOS ONE*
Powell, A. A., Talasaz, A. H., Zhang, H., Coram, M. A., Reddy, A., Deng, G., Telli, M. L., Advani, R. H., Carlson, R. W., Mollick, J. A., Sheth, S., Kurian, A. W., Ford, et al
2012; 7 (5)

- **Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomol-induced oxidative DNA damage**
Alli, E., Ford, J. M.
AMER ASSOC CANCER RESEARCH.2012
- **Accuracy of BRCA1/2 Mutation Prediction Models for Different Ethnicities and Genders: Experience in a Southern Chinese Cohort** *WORLD JOURNAL OF SURGERY*
Kwong, A., Wong, C. H., Suen, D. T., Co, M., Kurian, A. W., West, D. W., Ford, J. M.
2012; 36 (4): 702-713
- **Intensity-Modulated Radiotherapy for Pancreatic Adenocarcinoma** *51st Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO)*
Abelson, J. A., Murphy, J. D., Minn, A. Y., Chung, M., Fisher, G. A., Ford, J. M., Kunz, P., Norton, J. A., Visser, B. C., Poultides, G. A., Koong, A. C., Chang, D. T.
ELSEVIER SCIENCE INC.2012: E595–E601
- **Family History As a Positive Prognostic Factor in Gastric Cancer** *JOURNAL OF CLINICAL ONCOLOGY*
Nadauld, L. D., Ford, J. M.
2012; 30 (7): 683-684
- **Identification of a Functional In Vivo p53 Response Element in the Coding Sequence of the Xeroderma Pigmentosum Group C Gene.** *Genes & cancer*
Hastak, K., Adimoolam, S., Trinklein, N. D., Myers, R. M., Ford, J. M.
2012; 3 (2): 131-140
- **HER2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma in a US Population: Clinicopathologic Analysis With Proposed Approach to HER2 Assessment** *APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY*
Kunz, P. L., Mojtahed, A., Fisher, G. A., Ford, J. M., Chang, D. T., Balise, R. R., Bangs, C. D., Cherry, A. M., Pai, R. K.
2012; 20 (1): 13-24
- **Quantitative and Sensitive Detection of Cancer Genome Amplifications from Formalin Fixed Paraffin Embedded Tumors with Droplet Digital PCR.** *Translational medicine (Sunnyvale, Calif.)*
Nadauld, L., Regan, J. F., Miotke, L., Pai, R. K., Longacre, T. A., Kwok, S. S., Saxonov, S., Ford, J. M., Ji, H. P.
2012; 2 (2)
- **A rare case of an aldosterone secreting metastatic adrenocortical carcinoma and papillary thyroid carcinoma in a 31-year-old male.** *Rare tumors*
Wanta, S. M., Basina, M., Chang, S. D., Chang, D. T., Ford, J. M., Greco, R., Kingham, K., Merritt, R. E., Kunz, P. L.
2011; 3 (4)
- **A Prospective Study of Total Gastrectomy for CDH1-Positive Hereditary Diffuse Gastric Cancer** *ANNALS OF SURGICAL ONCOLOGY*
Chen, Y., Kingham, K., Ford, J. M., Rosing, J., Van Dam, J., Jeffrey, R. B., Longacre, T. A., Chun, N., Kurian, A., Norton, J. A.
2011; 18 (9): 2594-2598
- **SINGLE-FRACTION STEREOTACTIC BODY RADIATION THERAPY AND SEQUENTIAL GEMCITABINE FOR THE TREATMENT OF LOCALLY ADVANCED PANCREATIC CANCER** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Schellenberg, D., Kim, J., Cristman-Skieller, C., Chun, C. L., Columbo, L. A., Ford, J. M., Fisher, G. A., Kunz, P. L., Van Dam, J., Quon, A., Desser, T. S., Norton, J., Hsu, et al
2011; 81 (1): 181-188
- **Intensity-Modulated Radiation Therapy Versus Conventional Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal** *CANCER*
Bazan, J. G., Hara, W., Hsu, A., Kunz, P. A., Ford, J., Fisher, G. A., Welton, M. L., Shelton, A., Kapp, D. S., Koong, A. C., Goodman, K. A., Chang, D. T.
2011; 117 (15): 3342-3351
- **A two-antibody mismatch repair protein immunohistochemistry screening approach for colorectal carcinomas, skin sebaceous tumors, and gynecologic tract carcinomas** *MODERN PATHOLOGY*
Mojtahed, A., Schrijver, I., Ford, J. M., Longacre, T. A., Pai, R. K.
2011; 24 (7): 1004-1014
- **Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry** *BREAST CANCER RESEARCH AND TREATMENT*
Telli, M. L., Chang, E. T., Kurian, A. W., Keegan, T. H., McClure, L. A., Lichtensztajn, D., Ford, J. M., Gomez, S. L.
2011; 127 (2): 471-478
- **A novel de novo BRCA1 mutation in a Chinese woman with early onset breast cancer** *FAMILIAL CANCER*
Kwong, A., Ng, E. K., Tang, E. Y., Wong, C. L., Law, F. B., Leung, C. P., Chan, A., Cheung, M. T., To, M. Y., Ma, E. S., West, D. W., Ford, J. M.

2011; 10 (2): 233-237

- **Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers** *JOURNAL OF MEDICAL GENETICS*
Schrader, K. A., Masciari, S., Boyd, N., Salamanca, C., Senz, J., Saunders, D. N., Yorida, E., Maines-Bandiera, S., Kaurah, P., Tung, N., Robson, M. E., Ryan, P. D., Olopade, et al
2011; 48 (1): 64-68
- **Multimodality Therapy for Esophageal Cancer: The Benefit of Chemoradiation**
Vossler, S. R., Bavan, B., Kunz, P., Ford, J. M., Fisher, G. A., Whyte, R., Koong, A. C., Chang, D. T.
ELSEVIER SCIENCE INC.2011: S309-S309
- **PARP Inhibitors for the Treatment and Prevention of Breast Cancer.** *Current breast cancer reports*
Vinayak, S., Ford, J. M.
2010; 2 (4): 190-197
- **Expression of p16(INK4A) But Not Hypoxia Markers or Poly Adenosine Diphosphate-Ribose Polymerase Is Associated With Improved Survival in Patients With Pancreatic Adenocarcinoma** *51st Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO)*
Chang, D. T., Chapman, C. H., Norton, J. A., Visser, B., Fisher, G. A., Kunz, P., Ford, J. M., Koong, A. C., Pai, R. K.
WILEY-BLACKWELL.2010: 5179-87
- **Poly(ADP-Ribose) Polymerase Inhibition: "Targeted" Therapy for Triple-Negative Breast Cancer** *CLINICAL CANCER RESEARCH*
Anders, C. K., Winer, E. P., Ford, J. M., Dent, R., Silver, D. P., Sledge, G. W., Carey, L. A.
2010; 16 (19): 4702-4710
- **PARP inhibitors in breast cancer.** *Clinical advances in hematology & oncology : H&O*
Telli, M. L., Ford, J. M.
2010; 8 (9): 629-635
- **Comparison of Intensity-Modulated Radiotherapy and 3-Dimensional Conformal Radiotherapy as Adjuvant Therapy for Gastric Cancer** *51st Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO)*
Minn, A. Y., Hsu, A., La, T., Kunz, P., Fisher, G. A., Ford, J. M., Norton, J. A., Visser, B., Goodman, K. A., Koong, A. C., Chang, D. T.
JOHN WILEY & SONS INC.2010: 3943-52
- **Hereditary diffuse gastric cancer due to a previously undescribed CDH1 splice site mutation** *HUMAN PATHOLOGY*
Matsukuma, K. E., Mullins, F. M., Dietz, L., Zehnder, J. L., Ford, J. M., Chun, N. M., Schrijver, I.
2010; 41 (8): 1200-1203
- **(18)FLUORODEOXYGLUCOSE PET IS PROGNOSTIC OF PROGRESSION-FREE AND OVERALL SURVIVAL IN LOCALLY ADVANCED PANCREAS CANCER TREATED WITH STEREOTACTIC RADIOTHERAPY** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Schellenberg, D., Quon, A., Minn, A. Y., Graves, E. E., Kunz, P., Ford, J. M., Fisher, G. A., Goodman, K. A., Koong, A. C., Chang, D. T.
2010; 77 (5): 1420-1425
- **Pathological response after chemoradiation for T3 rectal cancer** *COLORECTAL DISEASE*
Chennupati, S. K., Kamaya, A., Fisher, G. A., Ford, J. M., Kunz, P., Itakura, H., Welton, M. L., Shelton, A., Van Dam, J., Koong, A. C., Chang, D. T.
2010; 12 (7): E24-E30
- **High-resolution melting analysis for rapid screening of BRCA2 founder mutations in Southern Chinese breast cancer patients** *BREAST CANCER RESEARCH AND TREATMENT*
Kwong, A., Ng, E. K., Law, F. B., Wong, L. P., To, M. Y., Cheung, M. T., Wong, H. N., Chan, V. W., Kurian, A., West, D. W., Ford, J. M., Ma, E. S.
2010; 122 (2): 605-607
- **Pathological response after chemoradiation for T3 rectal cancer.** *Colorectal disease*
Chennupati, S. K., Kamaya, A., Fisher, G. A., Ford, J. M., Kunz, P., Itakura, H., Welton, M. L., Shelton, A., Van Dam, J., Koong, A. C., Chang, D. T.
2010; 12 (7 Online): e24-30
- **Novel Treatment Approaches for Triple-Negative Breast Cancer** *CLINICAL BREAST CANCER*
Telli, M. L., Ford, J. M.
2010; 10: E16-E22
- **Longer Relative Telomere Length in Blood from Women with Sporadic and Familial Breast Cancer Compared with Healthy Controls** *CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION*

- Gramatges, M. M., Telli, M. L., Balise, R., Ford, J. M.
2010; 19 (2): 605-613
- **Oncogenic BRAF Mutation with CDKN2A Inactivation Is Characteristic of a Subset of Pediatric Malignant Astrocytomas** *CANCER RESEARCH*
Schiffman, J. D., Hodgson, J. G., VandenBerg, S. R., Flaherty, P., Polley, M. C., Yu, M., Fisher, P. G., Rowitch, D. H., Ford, J. M., Berger, M. S., Ji, H., Gutmann, D. H., James, et al
2010; 70 (2): 512-519
 - **Multimodality treatment with intensity modulated radiation therapy for esophageal cancer** *DISEASES OF THE ESOPHAGUS*
La, T. H., Minn, A. Y., Su, Z., Fisher, G. A., Ford, J. M., Kunz, P., Goodman, K. A., Koong, A. C., Chang, D. T.
2010; 23 (4): 300-308
 - **Intensity Modulated Radiation Therapy vs. Conventional Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal** *52nd Annual Meeting of the American-Society-for-Therapeutic-Radiation-Oncology (ASTRO)*
Bazan, J. G., Hara, W., Kunz, P., Fisher, G. A., Ford, J. M., Welton, M. L., Koong, A., Shelton, A., Goodman, K. A., Chang, D. T.
ELSEVIER SCIENCE INC.2010: S300–S301
 - **NCCN clinical practice guidelines in oncology. Colorectal cancer screening.** *Journal of the National Comprehensive Cancer Network*
Burt, R. W., Barthel, J. S., Dunn, K. B., David, D. S., Drelichman, E., Ford, J. M., Giardiello, F. M., Gruber, S. B., Halverson, A. L., Hamilton, S. R., Ismail, M. K., Jaspersen, K., Lazenby, et al
2010; 8 (1): 8-61
 - **Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis** *JOURNAL OF TRANSLATIONAL MEDICINE*
Chang, S. T., Zahn, J. M., Horecka, J., Kunz, P. L., Ford, J. M., Fisher, G. A., Le, Q. T., Chang, D. T., Ji, H., Koong, A. C.
2009; 7
 - **ASSOCIATION OF 7Q34 COPY NUMBER GAINS AND KIAA1549-BRAF GENE FUSIONS WITH JUVENILE PILOCYTIC ASTROCYTOMA**
Hodgson, J., VandenBerg, S. R., James, C., Perry, A., Gutmann, D., Fisher, P., Ford, J., Ji, H., Schiffman, J.
OXFORD UNIV PRESS INC.2009: 960
 - **A BRCA2 founder mutation and seven novel deleterious BRCA mutations in southern Chinese women with breast and ovarian cancer** *BREAST CANCER RESEARCH AND TREATMENT*
Kwong, A., Wong, L. P., Wong, H. N., Law, F. B., Ng, E. K., Tang, Y. H., Chan, W. K., Ho, L. S., Kwan, K. H., Poon, M., Wong, T. T., Leung, F. C., Chan, et al
2009; 117 (3): 683-686
 - **Molecular inversion probes reveal patterns of 9p21 deletion and copy number aberrations in childhood leukemia** *CANCER GENETICS AND CYTOGENETICS*
Schiffman, J. D., Wang, Y., McPherson, L. A., Welch, K., Zhang, N., Davis, R., Lacayo, N. J., Dahl, G. V., Faham, M., Ford, J. M., Ji, H. P.
2009; 193 (1): 9-18
 - **The role of the retinoblastoma/E2F1 tumor suppressor pathway in the lesion recognition step of nucleotide excision repair** *DNA REPAIR*
Lin, P. S., McPherson, L. A., Chen, A. Y., Sage, J., Ford, J. M.
2009; 8 (7): 795-802
 - **Detection of Solitary Humeral Metastasis From Pancreatic Adenocarcinoma With F-18 FDG PET/CT** *CLINICAL NUCLEAR MEDICINE*
Kim, J., Quon, A., Humke, E., Ford, J. M., Koong, A. C.
2009; 34 (5): 312-313
 - **Stereotactic Radiotherapy for Unresectable Adenocarcinoma of the Pancreas** *CANCER*
Chang, D. T., Schellenberg, D., Shen, J., Kim, J., Goodman, K. A., Fisher, G. A., Ford, J. M., Desser, T., Quon, A., Koong, A. C.
2009; 115 (3): 665-672
 - **Tailoring BRCA PRO to Asian-Americans IN REPLY** *JOURNAL OF CLINICAL ONCOLOGY*
Kurian, A. W., Whittemore, A. S., Ford, J. M.
2009; 27 (4): 643–44
 - **Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Schellenberg, D., Goodman, K. A., Lee, F., Chang, S., Kuo, T., Ford, J. M., Fisher, G. A., Quon, A., Desser, T. S., Norton, J., Greco, R., Yang, G. P., Koong, et al
2008; 72 (3): 678-686

- **Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger** *95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology*
Jensen, K. C., Mariappan, M. R., Putcha, G. V., Husain, A., Chun, N., Ford, J. M., Schrijver, I., Longacre, T. A.
LIPPINCOTT WILLIAMS & WILKINS.2008: 1029-37
- **Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers** *FAMILIAL CANCER*
Staton, A. D., Kurian, A. W., Cobb, K., Mills, M. A., Ford, J. M.
2008; 7 (2): 179-186
- **Risk-reducing total gastrectomy for germline mutations in E-cadherin (CDH1): Pathologic findings with clinical implications** *AMERICAN JOURNAL OF SURGICAL PATHOLOGY*
Rogers, W. M., Dobo, E., Norton, J. A., Van Dam, J., Jeffrey, R. B., Huntsman, D. G., Kingham, K., Chun, N., Ford, J. M., Longacre, T. A.
2008; 32A (6): 799-809
- **Risk-reducing total gastrectomy for germline mutations in E-cadherin (CDH1): pathologic findings with clinical implications.** *American journal of surgical pathology*
Rogers, W. M., Dobo, E., Norton, J. A., Van Dam, J., Jeffrey, R. B., Huntsman, D. G., Kingham, K., Chun, N., Ford, J. M., Longacre, T. A.
2008; 32 (6): 799-809
- **Characterization of the pathogenic mechanism of a novel BRCA2 variant in a Chinese family** *FAMILIAL CANCER*
Kwong, A., Wong, L. P., Chan, K. Y., Ma, E. S., Khoo, U. S., Ford, J. M.
2008; 7 (2): 125-133
- **Preliminary activity of XL880, a dual MET/VEGFR2 inhibitor, in MET amplified poorly differentiated gastric cancer (PDGC): Interim results of a multicenter phase II study**
Jhaver, M. P., Kindler, H. L., Wainberg, Z. A., Hecht, J. R., Kerr, R. O., Ford, J. M., Henderson, C., Mueller, T., KEER, H. N., Shah, M. A.
AMER SOC CLINICAL ONCOLOGY.2008
- **Identification of a novel p53 in-frame deletion in a Li-Fraumeni-like family** *PEDIATRIC BLOOD & CANCER*
Schiffman, J. D., Chun, N., Fisher, P. G., Dahl, G. V., Ford, J. M., Eggerding, F. A.
2008; 50 (4): 914-916
- **Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations - Reply** *ANNALS OF SURGERY*
Norton, J. A., Ford, J. M.
2008; 247 (4): 715-16
- **Magnetic resonance galactography: A feasibility study in women with prior atypical breast duct cytology** *BREAST JOURNAL*
Kurian, A. W., Hartman, A., Mills, M. A., Logan, L. J., Sawyer, A. M., Ford, J. M., Daniel, B. L.
2008; 14 (2): 211-214
- **HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Adimoolam, S., Sirisawad, M., Chen, J., Thiemann, P., Ford, J. M., Buggy, J. J.
2007; 104 (49): 19482-19487
- **A carrier of both MEN1 and BRCA2 mutations: case report a-lid review of the literature** *CANCER GENETICS AND CYTOGENETICS*
Ghataorhe, P., Kurian, A. W., Pickart, A., Trapane, P., Norton, J. A., Kingham, K., Ford, J. M.
2007; 179 (2): 89-92
- **Identification of an intronic single nucleotide polymorphism leading to allele dropout during validation of a CDH1 sequencing assay: implications for designing polymerase chain reaction-based assays** *GENETICS IN MEDICINE*
Mullins, F. M., Dietz, L., Lay, M., Zehnder, J. L., Ford, J., Chun, N., Schrijver, I.
2007; 9 (11): 752-760
- **Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer** *JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION*
Kaurah, P., MacMillan, A., Boyd, N., Senz, J., De Luca, A., Chun, N., Suriano, G., Zaor, S., Van Manen, L., Gilpin, C., Nikkel, S., Connolly-Wilson, M., Weissman, et al
2007; 297 (21): 2360-2372
- **Ductal pattern enhancement on magnetic resonance imaging of the breast due to ductal lavage** *BREAST JOURNAL*
Ghanouni, P., Kurian, A. W., Margolis, D., Hartman, A., Mills, M. A., Plevritis, S. K., Ford, J. M., Daniel, B. L.

2007; 13 (3): 281-286

- **Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells** *MOLECULAR PHARMACOLOGY*
Alli, E., Yang, J., Ford, J. M., Hait, W. N.
2007; 71 (5): 1233-1240
- **Germ line mutations of mismatch repair genes in hereditary nonpolyposis colorectal cancer patients with small bowel cancer: International Society for Gastrointestinal Hereditary Tumours Collaborative Study** *CLINICAL CANCER RESEARCH*
Park, J., Kim, D., Hong, C. W., Nam, B., Shin, Y., Hong, S., Kim, I., Lim, S., Aronson, M., Bisgaard, M. L., Brown, G. J., Burn, J., Chow, et al
2006; 12 (11): 3389-3393
- **A kinase-independent function of c-Abl in promoting proteolytic destruction of damaged DNA binding proteins** *MOLECULAR CELL*
Chen, X., Zhang, J., Lee, J., Lin, P. S., Ford, J. M., Zheng, N., Zhou, P.
2006; 22 (4): 489-499
- **Colorectal Cancer Screening Clinical Practice Guidelines.** *Journal of the National Comprehensive Cancer Network*
Levin, B., Barthel, J. S., Burt, R. W., David, D. S., Ford, J. M., Giardiello, F. M., Gruber, S. B., Halverson, A. L., Hamilton, S., Kohlmann, W., Ludwig, K. A., Lynch, P. M., Marino, et al
2006; 4 (4): 384-420
- **Genetic/familial high-risk assessment: breast and ovarian.** *Journal of the National Comprehensive Cancer Network*
Daly, M. B., Axilbund, J. E., Bryant, E., Buys, S., Eng, C., Friedman, S., Esserman, L. J., Farrell, C. D., Ford, J. M., Garber, J. E., Jeter, J. M., Kohlmann, W., Lynch, et al
2006; 4 (2): 156-176
- **Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Koong, A. C., Christofferson, E., Le, Q. T., Goodman, K. A., Ho, A., Kuo, T., Ford, J. M., Fisher, G. A., Greco, R., Norton, J., Yang, G. P.
2005; 63 (2): 320-323
- **Regulation of DNA damage recognition and nucleotide excision repair: Another role for p53** *MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS*
Ford, J. M.
2005; 577 (1-2): 195-202
- **Opinions of women with high inherited breast cancer risk about prophylactic mastectomy: an initial evaluation from a screening trial including magnetic resonance imaging and ductal lavage** *HEALTH EXPECTATIONS*
Kurian, A. W., Hartman, A. R., Mills, M. A., Ford, J. M., Daniel, B. L., Plevritis, S. K.
2005; 8 (3): 221-233
- **Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer** *40th Annual Meeting of the American-Society-of-Clinical-Oncology*
Kuo, T., Cho, C. D., Halsey, J., Wakelee, H. A., Advani, R. H., Ford, J. M., Fisher, G. A., Sikic, B. I.
AMER SOC CLINICAL ONCOLOGY.2005: 5613-19
- **Characterization of a recurrent germ line mutation of the E-cadherin gene: Implications for genetic testing and clinical management** *CLINICAL CANCER RESEARCH*
Suriano, G., Yew, S., Ferreira, P., Senz, J., Kaurah, P., Ford, J. M., Longacre, T. A., NORTON, J. A., Chun, N., Young, S., Oliveira, M. J., MacGillivray, B., Rao, et al
2005; 11 (15): 5401-5409
- **Ductal lavage of fluid-yielding and non-fluid-yielding ducts in BRCA1 and BRCA2 mutation carriers and other women at high inherited breast cancer risk** *CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION*
Kurian, A. W., Mills, M. A., Jaffee, M., Sigal, B. M., Chun, N. M., Kingham, K. E., Collins, L. C., Nowels, K. W., Plevritis, S. K., Garber, J. E., Ford, J. M., Hartman, A. R.
2005; 14 (5): 1082-1089
- **Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Koong, A. C., Le, Q. T., Ho, A., Fong, B., Fisher, G., Cho, C., Ford, J., Poen, J., Gibbs, I. C., Mehta, V. K., Kee, S., Trueblood, W., Yang, et al
2004; 58 (4): 1017-1021

- **Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma** *CANCER*
Hartman, A. R., Daniel, B. L., Kurian, A. W., Mills, M. A., Nowels, K. W., Dirbas, F. M., Kingham, K. E., Chun, N. M., Herfkens, R. J., Ford, J. M., Plevritis, S. K.
2004; 100 (3): 479-489
- **Functional characterization of global genomic DNA repair and its implications for cancer** *4th International Conference on Environmental Mutagens in Human Populations (ICEMHP)*
Hanawalt, P. C., Ford, J. A., Lloyd, D. R.
ELSEVIER SCIENCE BV.2003: 107-14
- **BRCA1 and p53: compensatory roles in DNA repair** *JOURNAL OF MOLECULAR MEDICINE-IMM*
Hartman, A. R., Ford, J. M.
2003; 81 (11): 700-707
- **Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Karlsson, A., Deb-Basu, D., Cherry, A., Turner, S., Ford, J., Felsner, D. W.
2003; 100 (17): 9974-9979
- **Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Mehta, V. K., Cho, C., Ford, J. M., Jambalos, C., Poen, J., Koong, A., Lin, A., Bastidas, J. A., Young, H., Dunphy, E. P., Fisher, G.
2003; 55 (1): 132-137
- **DNA Damage, Repair, and Diseases.** *Journal of biomedicine & biotechnology*
Wiesmüller, L., Ford, J. M., Schiestl, R. H.
2002; 2 (2): 45
- **The p53-regulated cyclin-dependent kinase inhibitor, p21 (cip1, waf1, sdi1), is not required for global genomic and transcription-coupled nucleotide excision repair of UV-induced DNA photoproducts** *JOURNAL OF BIOLOGICAL CHEMISTRY*
Adimoolam, S., Lin, C. X., Ford, J. M.
2001; 276 (28): 25813-25822
- **Protracted venous infusion 5-fluorouracil with concomitant radiotherapy compared with bolus 5-fluorouracil for unresectable pancreatic cancer** *AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS*
Mehta, V. K., Poen, J. C., Ford, J. M., Oberhelman, H. A., Vierra, M. A., Bastidas, A. J., Fisher, G. A.
2001; 24 (2): 155-159
- **Radiotherapy, concomitant protracted-venous-infusion 5-fluorouracil, and surgery for ultrasound-staged T3 or T4 rectal cancer** *36th Annual Meeting of the American-Society-of-Clinical-Oncology*
Mehta, V. K., Poen, J., Ford, J., Edelstein, P. S., Vierra, M., Bastidas, A. J., Young, H., Fisher, G.
SPRINGER.2001: 52-58
- **Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas** *82nd Annual Meeting of the American-Radium-Society*
Mehta, V. K., Fisher, G., Ford, J. A., Poen, J. C., Vierra, M. A., Oberhelman, H., Niederhuber, J., Bastidas, J. A.
SPRINGER.2001: 27-35
- **Adjuvant chemoradiotherapy for "unfavorable" carcinoma of the ampulla of vater - Preliminary report** *ARCHIVES OF SURGERY*
Mehta, V. K., Fisher, G. A., Ford, J. M., Poen, J. C., Vierra, M. A., Oberhelman, H. A., Bastidas, A. J.
2001; 136 (1): 65-69
- **Adjuvant radiotherapy and concomitant 5-fluorouracil by protracted venous infusion for resected pancreatic cancer** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Mehta, V. K., Fisher, G. A., Ford, J. M., Oberhelman, H. A., Vierra, M. A., Bastidas, A. J., Poen, J. C.
2000; 48 (5): 1483-1487
- **Proapoptotic p53-interacting protein 53BP2 is induced by UV irradiation but suppressed by p53** *MOLECULAR AND CELLULAR BIOLOGY*
Lopez, C. D., Ao, Y., Rohde, L. H., Perez, T. D., O'Connor, D. J., Lu, X., Ford, J. M., Naumovski, L.
2000; 20 (21): 8018-8025
- **Reduced global genomic repair of ultraviolet light-induced cyclobutane pyrimidine dimers in simian virus 40-transformed human cells** *MOLECULAR CARCINOGENESIS*

- Bowman, K. K., Sicard, D. M., Ford, J. M., Hanawalt, P. C.
2000; 29 (1): 17-24
- **Decreased UV sensitivity, mismatch repair activity and abnormal cell cycle checkpoints in skin cancer cell lines derived from UVB-irradiated XPA-deficient mice** *MUTATION RESEARCH-DNA REPAIR*
Ichikawa, M., Nakane, H., Marra, G., Corti, C., Jiricny, J., Fitch, M., Ford, J. M., Ikejima, M., Shimada, T., Yoshino, M., Takeuchi, S., Nakatsu, Y., Tanaka, et al
2000; 459 (4): 285-298
 - **p53-mediated DNA repair responses to UV radiation: Studies of mouse cells lacking p53, p21, and/or gadd45 genes** *MOLECULAR AND CELLULAR BIOLOGY*
Smith, M. L., Ford, J. M., Hollander, M. C., Bortnick, R. A., Amundson, S. A., Seo, Y. R., Deng, C. X., Hanawalt, P. C., Fornace, A. J.
2000; 20 (10): 3705-3714
 - **Chemoradiotherapy in the management of localized tumors of the pancreas** *ANNALS OF SURGICAL ONCOLOGY*
Poen, J. C., Ford, J. M., Niederhuber, J. E.
1999; 6 (1): 117-122
 - **Hepatitis B x protein inhibits p53-dependent DNA repair in primary mouse hepatocytes** *JOURNAL OF BIOLOGICAL CHEMISTRY*
Prost, S., Ford, J. M., Taylor, G., Doig, J., Harrison, D. J.
1998; 273 (50): 33327-33332
 - **Human fibroblasts expressing the human papillomavirus E6 gene are deficient in global genomic nucleotide excision repair and sensitive to ultraviolet irradiation** *CANCER RESEARCH*
Ford, J. M., Baron, E. L., Hanawalt, P. C.
1998; 58 (4): 599-603
 - **Role of DNA excision repair gene defects in the etiology of cancer** *GENETIC INSTABILITY AND TUMORIGENESIS*
Ford, J. M., Hanawalt, P. C.
1997; 221: 47-70
 - **Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers** *EUROPEAN JOURNAL OF CANCER*
Ford, J. M.
1996; 32A (6): 991-1001
 - **P-glycoprotein-mediated multidrug resistance: experimental and clinical strategies for its reversal.** *Cancer treatment and research*
Ford, J. M., Yang, J. M., Hait, W. N.
1996; 87: 3-38
 - **MODULATORS OF MULTIDRUG-RESISTANCE - PRECLINICAL STUDIES** *HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA*
Ford, J. M.
1995; 9 (2): 337-361
 - **PREFERENTIAL REPAIR OF ULTRAVIOLET LIGHT-INDUCED DNA-DAMAGE IN THE TRANSCRIBED STRAND OF THE HUMAN P53 GENE** *MOLECULAR CARCINOGENESIS*
Ford, J. M., Lommel, L., Hanawalt, P. C.
1994; 10 (2): 105-109
 - **PHARMACOLOGICAL CIRCUMVENTION OF MULTIDRUG-RESISTANCE** *CYTOTECHNOLOGY*
Ford, J. M., Hait, W. N.
1993; 12 (1-3): 171-212
 - **EFFECT OF BUTHIONINE SULFOXIMINE ON TOXICITY OF VERAPAMIL AND DOXORUBICIN TO MULTIDRUG RESISTANT CELLS AND TO MICE** *CANCER RESEARCH*
Ford, J. M., Yang, J. M., Hait, W. N.
1991; 51 (1): 67-72
 - **MODULATION OF RESISTANCE TO ALKYLATING-AGENTS IN CANCER CELL BY GOSSYPOL ENANTIOMERS** *CANCER LETTERS*
Ford, J. M., Hait, W. N., Matlin, S. A., Benz, C. C.
1991; 56 (1): 85-94
 - **PHARMACOLOGY OF DRUGS THAT ALTER MULTIDRUG RESISTANCE IN CANCER** *PHARMACOLOGICAL REVIEWS*

Ford, J. M., Hait, W. N.
1990; 42 (3): 155-199

● **BIOCHEMICAL CORRELATES OF THE ANTITUMOR AND ANTIMITOCHONDRIAL PROPERTIES OF GOSSYPOL ENANTIOMERS** *MOLECULAR PHARMACOLOGY*

Benz, C. C., Keniry, M. A., Ford, J. M., Townsend, A. J., COX, F. W., PALAYOOR, S., Matlin, S. A., Hait, W. N., COWAN, K. H.
1990; 37 (6): 840-847

● **CELLULAR AND BIOCHEMICAL-CHARACTERIZATION OF THIOXANTHENES FOR REVERSAL OF MULTIDRUG RESISTANCE IN HUMAN AND MURINE CELL-LINES** *CANCER RESEARCH*

Ford, J. M., Bruggemann, E. P., Pastan, I., Gottesman, M. M., Hait, W. N.
1990; 50 (6): 1748-1756

● **TOREMIFENE - PHARMACOLOGIC AND PHARMACOKINETIC BASIS OF REVERSING MULTIDRUG RESISTANCE** *JOURNAL OF CLINICAL ONCOLOGY*

DeGregorio, M. W., Ford, J. M., Benz, C. C., Wiebe, V. J.
1989; 7 (9): 1359-1364

● **STRUCTURAL FEATURES DETERMINING ACTIVITY OF PHENOTHIAZINES AND RELATED DRUGS FOR INHIBITION OF CELL-GROWTH AND REVERSAL OF MULTIDRUG RESISTANCE** *MOLECULAR PHARMACOLOGY*

Ford, J. M., Prozialeck, W. C., Hait, W. N.
1989; 35 (1): 105-115